

REPORT OF THE 384th CELL EXCHANGE

FEBRUARY 4, 2015

B-cell Lines	509-510
Cells	1533-1536
Serum	1161-1168

B-cell Line Exchange #255

The results for B-cell Line Exchange #255 are summarized in Tables 1 - 2 and individual laboratory results reported for each sample are listed in

Tables 3 - 6. The haplotype frequencies used in this report are from the NMDP Bioinformatics website, <http://bioinformatics.nmdp.org/>.

Ter-509. The consensus type for this Caucasian sample is DRB1*01:03-DRB1*15:01-DRB5*01:01-DQA1*01:02-DQA1*05:05-DQB1*03:01-DQB1*06:02-DPA1*01:03-DPB1*02:01-DPB1*04:02-A*02:01-A*03:01-B*15:01-B*27:05-C*01:02-C*03:03. One likely haplotype in this cell is DRB1*01:03-DQA1*05:05-DQB1*03:01. The DRB1*01:03-DQB1*03:01 association in this cell is observed in Caucasian populations, with HF=0.00203. Previous DRB1*01:03 exchange cells such as Ter 428 (same as Ter 310 and Ter 290), Ter 417, and Ter 418 were found in association with DQB1*05:01. The other likely haplotype in this cell is DRB1*15:01-DRB5*01:01-DQA1*01:02-DQB1*06:02, as observed in a number of previous exchange cells, most recently, Ter 488 (same as Ter 135) and Ter 468 (Ter 398 and Ter 362).

This cell was previously typed as Ter 270 (2000) and Ter 73 (1990), as astutely noted by Lopez-Cepero. In this present retyping, DQA1*05:05 was assigned by 36%, compared to only 11% of labs assigning DQA1*05:05 in 2000. Despite the increase in the detection of DQA1*05:05, there were a number of labs (n=11) that were unable to resolve DQA1*05:05 from DQA1*05:09 and DQA1*05:11. DR103 (100%) and DR15 (100%) were reported by serology and confirmed as DRB1*01:03 (75%) and DRB1*15:01 (47%).

Ter-510. The consensus type for this Black sample is DRB1*04:04-DRB1*09:01-DRB4*01:01-DRB4*01:03-DQA1*03:01-DQA1*03:03-DQB1*02:02-DQB1*03:02-DPA1*01:03-DPB1*02:01-DPB1*03:01-A*24:02-A*33:03-B*15:07-B*15:16-C*03:03-C*14:02. One likely haplotype in this cell is DRB1*04:04-DRB4*01:03-DQA1*03:03-DQB1*03:02. The association of DRB1*04:04 with DQB1*03:02 is observed commonly across all populations, with HF=0.00650, in African Americans. The other probable haplotype in this cell is DRB1*09:01-DRB4*01:01-DQA1*03:01-DQB1*02:02. This remains the only DRB1*09:01 cell typed in the exchange to be associated with DQB1*02:02. All other previous DRB1*09:01 exchange cells, such as Ter 489 (same as Ter 192 and Ter 69), Ter 163 (same as Ter 89), and Ter 137 (same as Ter 61), were associated with DQB1*03:03.

This cell was previously typed as Ter 257 (2000). We congratulate Lopez-Cepero for correctly identifying this cell as being previously typed. In this present retyping, DRB1*09:01 was assigned by 34%, a decrease from a detection level of 86% back in 2000. DRB1*09 was reported by 40%, with an additional 8 labs reporting DRB1*09:01/21. DRB1*09:21 differs from DRB1*09:01 by a single nucleotide substitution in exon 4 at codon 196 (CAG → CGG), resulting in an amino acid change from glutamine to arginine. DRB1*04:04 was assigned by 51% as the second DRB1 type, with 6 labs assigning DRB1*04:04:01.

Table 1: Summary of the 255th B-cell Line Exchange

Ter-509																	
DNA Typing - class II	57 LABS - DRB1		%(n)	40 LABS - DRB5		33 LABS - DQA1		%(n)	55 LABS - DQB1		%(n)	14 LABS - DPA1		%(n)	29 LABS - DPB1		%(n)
	DRB1*01:03	75(43)		DRB5*01:01:01	3 (1)	DQA1*01:02:01:01	3 (1)	DQB1*03:01:01	4 (2)	DPA1*01:03:01G	7 (1)	DPB1*02:01:02	3 (1)				
	DRB1*01:03/39N	5 (3)		DRB5*01:01	63(25)	DQA1*01:02:01G	3 (1)	DQB1*03:01:01G	2 (1)	DPA1*01:03	79 (11)	DPB1*02:01:02G	10(3)				
	DRB1*01	19(11)		DRB5*01:01+	3 (1)	DQA1*01:02	39(13)	DQB1*03:01	47(26)	DPA1*01	14(2)	DPB1*02:01P	3 (1)				
				DRB5*01	13(5)	DQA1*01:02+	27(9)	DQB1*03:01+	13(7)			DPB1*02:01	73(21)				
				DRB5*+	20(8)	DQA1*01	27(9)	DQB1*03(DQ7)	7 (4)			DPB1*02:01/*141:01	10(3)				
								DQB1*03	27(15)								
		DRB1*15:01:01	2 (1)				DQA1*05:05	36(12)	DQB1*06:02:01	4 (2)			DPB1*04:02:01	3 (1)			
	DRB1*15:01:01G	2 (1)				DQA1*05:05+	33(11)	DQB1*06:02:01G	2 (1)			DPB1*04:02:01G	7 (2)				
	DRB1*15:01	43(27)				DQA1*05	30(10)	DQB1*06:02	45(25)			DPB1*04:02P	3 (1)				
	DRB1*15:01+	12(7)						DQB1*06:02+	13(7)			DPB1*04:02	80(23)				
	DRB1*15	37(21)						DQB1*06	36(20)			DPB1*105:01	3 (1)				
												DPB1*02:01	3 (1)				
Serology - class II	4 LABS - DR		%(n)	DR51		4 LABS - DQ		%(n)	DQ7		4 LABS - DQ		%(n)	DQ6		50(2)	
	DR103	100(4)		DR51	100(4)	DQ7	100(4)	DQ6	50(2)	DQ1	50(2)	DQ6	50(2)				
		DR15	100(4)														
DNA Typing - class I	37 LABS - HLA-A		%(n)	37 LABS - HLA-B		37 LABS - HLA-C		%(n)	A*03:01:01:01		B*27:05:02		C*03:03:01		5 (2)		
	A*02:01:01:01	5 (2)		B*15:01:01:01	5 (2)	C*01:02:01	5 (2)	A*03:01:01	3 (1)	B*27:05:02G	3 (1)	C*03:03:01G	3 (1)				
	A*02:01:01:01	3 (1)		B*15:01:01:01+	3 (1)	C*01:02:01G	3 (1)	A*03:01	30(11)	B*27:05	16(6)	C*03:03	30(11)				
	A*02:01	24(9)		B*15:01	32(12)	C*01:02	22(8)	A*03:01+	14(5)	B*27:05+	27(10)	C*03:03+	14(5)				
	A*02:01+	19(7)		B*15:01+	14(5)	C*01:02+	19(7)	A*03:01+	14(5)	B*27:05+	27(10)	C*03(Cw9)	8 (3)				
	A*02	49(18)		B*15(B62)	8 (3)	C*01	51(19)	A*03	49(18)	B*27	49(18)	C*03	41(15)				
				B*15	38(14)												

Table 2: Summary of the 255th B-cell Line Exchange

Ter-510

	<u>58 LABS - DRB1</u>		%(n)	<u>40 LABS - DRB4</u>		%(n)	<u>32 LABS - DQA1</u>		%(n)	<u>55 LABS - DQB1</u>		%(n)	<u>14 LABS - DPA1</u>		%(n)	<u>29 LABS - DPB1</u>		%(n)				
	DNA Typing - class II	DRB1*04:04:01		11(6)	DRB4*01:01		27(11)	DQA1*03:01:01		3 (1)	DQB1*02:02:01		4 (2)	DPA1*01:03:01G		7 (1)	DPB1*02:01:02		3 (1)			
DRB1*04:04			40(23)	DRB4*01:01+		27(11)	DQA1*03:01:01G		3 (1)	DQB1*02:01:01G		2 (1)	DPA1*01:03		79(11)	DPB1*02:01:02G		10(3)				
DRB1*04:04+			11(6)	DRB4*01		25(10)	DQA1*03:01		63(20)	DQB1*02:02		47(26)	DPA1*01		14(2)	DPB1*02:01P		3 (1)				
DRB1*04			40(23)	DRB4*+		20(8)	DQA1*03:01+		6 (2)	DQB1*02:02+		13(7)				DPB1*02:01		76(22)				
							DQA1*03		25(8)	DQB1*02		34(19)				DPB1*02:01/*141:01		7 (2)				
		DRB1*09:01:02		3 (2)	<u>40 LABS - DRB4</u>		%(n)	DQA1*03:03:01		3 (1)	DQB1*03:02:01		5 (3)				DPB1*03:01:01		3 (1)			
		DRB1*09:01:02G		3 (2)	DRB4*01:03		42(17)	DQA1*03:01:01G		3 (1)	DQB1*03:02:01G		2 (1)				DPB1*03:01:01G		7 (2)			
	DRB1*09:01		28(16)	DRB4*01:01+		13(5)	DQA1*03:03		38(12)	DQB1*03:02		49(27)				DPB1*03:01P		10 (3)				
	DRB1*09:01+		12 (7)	DRB4*01		25(10)	DQA1*03:01+		22(7)	DQB1*03:02+		13(7)				DPB1*03:01		55(16)				
	DRB1*09:01/21		14(8)	DRB4*+		20(8)	DQA1*03		34(11)	DQB1*03 (DQ8)		7 (4)				DPB1*03:01/*104:01		24(7)				
	DRB1*09		40(23)							DQB1*03		24(13)										
Serology - class II	<u>4 LABS - DR</u>		%(n)				<u>4 LABS - DQ</u>		%(n)													
	DR4		100(4)				DR53		100(4)	DQ2		100(4)										
	DR9		100(4)										DQ8		75(3)							
									DQ3		25(1)											
DNA Typing - class I	<u>37 LABS - HLA-A</u>		%(n)	<u>37 LABS - HLA-B</u>		%(n)	<u>37 LABS - HLA-C</u>		%(n)													
	A*24:02		38(14)	B*15:07:01		11(4)	C*03:03:01		5 (2)													
	A*24:02+		14(5)	B*15:07		33(12)	C*03:03:01G		3 (1)													
	A*24		49(18)	B*15:07+		19(7)	C*03:03		27(10)													
				B*15(B62)		8 (3)	C*03:03+		16(6)													
				B*15		30(11)	C*03 (Cw9)		8 (3)													
							C*03		41(15)													
		A*33:03:01		11(4)	B*15:16:01		11(4)	C*14:02:01		8 (3)												
		A*33:03		30(11)	B*15:16		32(12)	C*14:02		30(11)												
		A*33:01+		11(4)	B*15:16+		19(7)	C*14:02+		11(4)												
		A*33		49(18)	B*15 (B63)		8 (3)	C*14		49(18)												
				B*15		30(11)	C*04		3 (1)													

Table 3: Individual laboratory results for B-cell #509-Class II

Center	Investigator	DRB1		DRB5	DQA1		DQB1		DPA1	DPB1		METHOD
5488	Adams, Sharon	*01:03	*15:01:01	*01:01	*01:02/11	*05:05/11	*03:01	*06:02		*02:01:02	*04:02:01	SSO, SBT, SSP
4691	Ajlan, Abdula	*01:03	*15:01				*03	*06				SSO
8038	Cao, Kai	*01:03	*15:01	*01:01:01	*01:02/08/09/11	*05:05/09/11	*03:01:01	*06:02:01	*01:03	*02:01	*04:02	SSO, SBT
774	Cecka, J. Mich	*01:03	*15:01/37/45+	*01:01	*01:02	*05:05	*03:01/21/22+	*06:02/33+	*01:03	*02:01/*141:01	*04:02	SSP
8070	Chang, Uckjin		*15									P-SSP
9916	Charlton, Ron	*01:03	*15:01	*01:01			*03:01/73/92+	*06:02/49/97+				SSP, SBT
4492	Charron, D.	*01:03	*15:01/74/75+	*01:01	*01:02/08/09/11	*05:05/09/11	*03:01/27/28+	*06:02/84+	*01:03	*02:01	*04:02	P-SSO, SSP
8021	Clark, Brendan	*01:03	*15:01	*01:01			*03:01	*06:02		*02:01	*04:02	P-SSP, RVSSO
3632	Colombe, Beth	*01:03	*15:01	*01:01	*01:02	*05:05	*03:01	*06:02				SSOP, SSP
5130	Costeas, Paul	*01:03	*15:01	*01:01	*01:02	*05:05	*03:01	*06:02				SSO, SSP
779	Daniel, Claud	*01:03	*15:01	*01:01	*01:02	*05:05/11	*03:01	*06	*01:03	*02:01	*04:02	P-SSP, SSO
5219	Daniel, Dolly	*01	*15				*03	*06				
3766	Dunn, Paul	*01:03	*15	*01	*01	*05	*03	*06	*01	*02:01	*04:02	RT-PCR, SSO, SSP
5214	Eckels/CPMC	*01:03	*15	*01:01	*01	*05	*03 (DQ7)	*06	*01:03	*02:01:02G	*04:02	SSOP
3135	Enczmann, J	*01:03	*15:01	*01:01			*03:01	*06:02		*02:01	*04:02	SBT, P-SSP, P-SSO
762	Fischer, Got	*01:03/39N	*15:01	*01:01	*01:02	*05:05	*03:01	*06:02		*02:01	*04:02	SSO, SBT
4079	Fort, Marylis	*01:03	*15:01/56/86		*01:02/08/09/11	*05:05/09/11	*03:01/27/28+	*06:02/84+		*02:01	*04:02	SSP, SSO-HD
792	Gandhi, Manis	*01:03	*15:01	*01:01	*01:02	*05:05	*03:01	*06:02		*02:01	*04:02	SSO, SSP
8043	Gideoni, Osnat	*01:03	*15:01		*01:02	*05:05	*03:01	*06:02	*01:03	*02:01	*04:02	SSP
9002	Gideoni_LR	*01	*15				*03	*06				SSO
910	Hahn, Amy B.	*01:03	*15	*+	*01:02	*05:05	*03:01	*06				SSP
810	Hamdi, Nuha	*01:03	*15:01/13/16+		*01:02/08/09/11	*05:05/09/11	*03:01/27/28+	*06:02/84+				SSO
2344	Hurley/Hartz	*01:03	*15:01:01G		*01:02:01:01	*05:05:01:01+	*03:01:01G	*06:02:01G	*01:03:01G	*02:01:02G	*04:02:01G	
771	Israel, Shosh	*01:03	*15:01				*03:01	*06:02				
9003	Israel_LR	*01	*15				*03	*06				P-SSO
794	Jaatinen, Tai	*01:03	*15:01/86	*01:01	*01:02/08/09/11	*05:05/09/11	*03:01	*06:02	*01:03	*02:01/*141:01	*04:02	SBT, SSO, SSP
5891	Jiang, Yueqin	NT										P-SBT
2847	Kihara, Masaaki	*01	*15									RVSSO
4337	Kim, Tai-Gyu	*01:03	*15:01				*03:01	*06:02		*02:01	*04:02	SBT, SSP
1694	Kissel&Hess	*01:03	*15	*+			*03:01	*06:02				SSP
168	Klein, Tirza	*01:03	*15:01				*03:01	*06:02				P-SSO, SSP
9000	Klein_LR	*01	*15				*03	*06				
87	Land, Geoffre	*01:03	*15:01	*01:01	*01:02	*05:05	*03:01	*06:02		*02:01	*04:02	SBT, SSO, SSP
725	Lardy, N.M.	*01	*15	*+	*01	*05	*03	*06				SSO, SSP
278	Lee, Jar-How	*01:03	*15:01	*01:01	*01:02	*05:05	*03:01	*06:02	*01:03	*02:01/*141:01	*04:02	SSP, RVSSOP
6649	Lim, Young Ae	*01	*15	*+								SSP
274	Lo, Raymundo	*01	*15:58		*01:02	*05	*03	*06:02	*01:03	*02:01	*02:01	SSO
731	Loewenthal, R	*01:03	*15:01				*03:01:01	*06:02:01				SBT, SSO
759	Lopez-Cepero	*01:03	*15:01/13/16+	*01:01	*01:02/08/09/11	*05:05/09/11	*03:01/27/28+	*06:02/84	*01:03	*02:01P	*04:02P	RVSSO
8052	Marcos, Cintia Y	*01:03	*15		*01:02/08/09/11	*05:05/09/11	*03	*06				P-SSO
206	McAlack-Hana	*01:03	*15	*01	*01	*05	*03 (DQ7)	*06				RVSSOP
8042	Muncher, Lior	*01:03	*15:01	*01:01			*03:01	*06:02				SSO, SSP
9001	Muncher_LR	*01	*15	*01			*03	*06				SSO, SSP
54	Pancoska, Ca	*01:03	*15	*01:01	*01	*05	*03 (DQ7)	*06	*01:03	*02:01	*04:02	RVSSO
3966	Permpikul&Ve	*01:03	*15:01	*01:01			*03:01	*06:02				P-SSP
2400	Phelan, Donna	*01:03	*15:01	*01	*01:02:01G	*05:05/09/11	*03:01	*06:02		*02:01	*105:01	SSO, SBT, SSP
8001	Rao, Prakash	*01:03	*15:01	*01:01	*01	*05	*03:01	*06:02		*02:01	*04:02	RVSSO, SSP
3753	Reed, Elaine	*01:03	*15:01	*01:01	*01:02/08/09/11	*05:05/09/11	*03:01	*06:02				SBT, SSO

Table 3: Individual laboratory results for B-cell #509-Class II

Center	Investigator	DRB1		DRB5	DQA1		DQB1		DPA1	DPB1		METHOD
3519	Renac, Virg	*01:03	*15:01	*01:01	*01:02	*05:05	*03:01	*06:02		*02:01	*04:02	SBT,P-SSP
3519	Renac, Virg_LR	*01:03/39N	*15				*03	*06		*02:01	*04:02	P-SSP
1160	Rosen-Bronson	*01:03	*15	*01:01			*03	*06				SSO
793	Rubocki, Rona	*01:03	*15	*+	*01	*05	*03 (DQ7)	*06		*02:01	*04:02	SSP
4251	Schiller, J	*01:03	*15:01	*01:01	*01	*05	*03:01	*06:02	*01	*02:01:02G	*04:02:01G	P-RVSSO, SBT
8068	Shanmugam, He	*01	*15	*+			*03	*06				P-SSP
1108	Sutherland, L	*01	*15	*01	*01	*05	*03	*06				SSOP
5451	Tilanus, Marc	*01:03	*15:01	*+			*03	*06				SBT, SSP
5462	Turner, E.V.	*01:03	*15:01	*01:01/15			*03:01/29	*06:02/115		*02:01	*04:02	SSP, SSO, SBT
5642	Varnavidou-N	*01:03/39N	*15:01/16	*+			*03:01	*06:02				P-SSP
3511	Zeevi, Adrian	*01:03	*15:01	*01:01	*01:02	*05:05	*03:01	*06:02		*02:01	*04:02	RVSSOP, SSP

CTR	DIRNAME	DR103	DR15	DR51			DQ7	DQ6	OTH1
4492	Charron, D	+	+	+			+	DQ1	DR13, DR52
910	Hahn, Amy B.	+	+	+			+	DQ1	
54	Pancoska, Car	+	+	+			+	+	
793	Rubocki, Rona	+	+	+			+	+	

Table 4: Individual laboratory results for B-cell #509-Class I

Center	Investigator	HLA-A		HLA-B		HLA-C		METHOD
5488	Adams,Sharon	*02:01/237	*03:01/05:01	*15:01/129/259	*27:05/13/67/70	*01	*03	SSO,SBT,SSP
4691	Ajlan,Abdula	*02	*03	*15	*27	*01	*03	SSO
8038	Cao,Kai	*02:01:01	*03:01:01:01+	*15:01:01:01+	*27:05/13	*01:02/85	*03:03/227	SSO,SBT
774	Cecka,J.Mich	*02	*03	*15	*27	*01	*03	SSP
9916	Charlton,Ron	*02:01:01:01	*03:01:01:01	*15:01:01:01	*27:05:02	*01:02:01	*03:03:01	SSP,SBT
4492	Charron,D.	*02:01/294/305N+	*03:01/118/129N+	*15:01/296	*27:05/96/104	*01:02/40/44/82+	*03:03/189N/192+	P-SSO,SSP
8021	Clark,Brendan	*02:01+	*03:01+	*15:01+	*27:03+	*01:02+	*03:03+	P-SSP,RVSSO
3632	Colombe,Beth	*02	*03	*15	*27	*01	*03	SSOP,SSP
5130	Costeas,Paul	*02:01	*03:01	*15:01	*27:05/56	*01:02/11/32	*03:03	SSO,SSP
779	Daniel,Claud	*02	*03	*15:01	*27	*01	*03:03	P-SSP,SSO
5219	Daniel,Dolly	*02	*03	*15	*27	*01	*03	SSO
3766	Dunn,Paul	*02	*03	*15	*27	*01	*03	RT-PCR,SSO,SSP
5214	Eckels/CPMC	*02	*03	*15 (B62)	*27	*01	*03 (Cw9)	SSO
3135	Enczmann,J	*02:01/01L	*03:01	*15:01	*27:05	*01:02	*03:03	SBT,P-SSP,P-SSO
792	Gandhi,Manis	*02:01	*03:01	*15:01	*27:05	*01:02	*03:03	SSO,SSP
810	Hamdi,Nuha	*02:01/01L/01Q/07+	*03:01/01N/03N+	*15:01/01N/26N+	*27:03/05/13/17+	*01:02/25/40/44/62+	*03:03/62/150/158+	SSO
2344	Hurley/Hartz	*02:01:01:01	*03:01:01:01	*15:01:01:01	*27:05:02	*01:02:01	*03:03:01	
794	Jaatinen,Tai	*02:01	*03:01	*15:01	*27:05/13	*01:02	*03:03	SBT,SSO,SSP
5891	Jiang,Yueqin	NT						P-SBT
2847	Kihara,Masaaki	*02	*03	*15	*27	*01	*03	RVSSO
4337	Kim,Tai-Gyu	*02:01	*03:01	*15:01	*27:05	*01:02	*03:03	SBT,SSP
1694	Kissel&Hess	*02	*03	*15	*27	*01	*03	SSP
278	Lee,Jar-How	*02:01	*03:01	*15:01	*27:05	*01:02	*03:03	SSP,RVSSOP
274	Lo,Raymundo	*02	*03	*15	*27	*01	*03	SSO
8052	Marcos,Cintia Y	*02	*03	*15	*27	*01	*03	P-SSO
206	McAlack-Hana	*02	*03	*15 (B62)	*27	*01	*03 (Cw9)	RVSSOP
8042	Muncher,Lior	*02:01	*03:01	*15:01	*27:05	*01:02	*03:03	SSO,SSP
9001	Muncher_LR	*02	*03	*15	*27	*01	*03	SSO,SSP
54	Pancoska,Ca	*02	*03	*15 (B62)	*27	*01	*03 (Cw9)	RVSSO
3966	Permpikul&Ve	*02	*03	*15	*27	*01	*03	P-SSP
2400	Phelan,Donna	*02:01	*03:01	*15:01	*27:05/13	*01:02/85	*03:03	SSO,SBT,SSP
3753	Reed,Elaine	*02:01/20/24/26+	*03:01/05/07/08+	*15:01/43/117+	*27:05/08/13/27+	*01:02/22/48/51+	*03:03/04/18/20N+	SBT,SSO
3519	Renac,Virginie	*02:01	*03:01	*15:01	*27:05/13	*01:02	*03:03	SBT,P-SSP
3519	Renac,Virginie_LR	*02	*03	*15	*27	*01	*03	P-SSP
4251	Schiller,J	*02:01	*03:01	*15:01	*27:05:02G	*01:02:01G	*03:03:01G	P-RVSSO,SBT
8068	Shanmugam,He	*02	*03	*15	*27	*01	*03	P-SSP
1108	Sutherland,L	*02	*03	*15	*27	*01	*03	SSO
5462	Turner,E.V.	*02:01/01L	*03:01	*15:01	*27:05	*01:02	*03:03	SSP,SSO,SBT

Table 5: Individual laboratory results for B-cell #510-Class II

Center	Investigator	DRB1		DRB4	DRB4	DQA1		DQB1		DPA1	DPB1		METHOD
5488	Adams,Sharon	*04:04:01	*09:01:02+	*01		*03:01	*03:03	*02:02:01	*03:02:01		*02:01:02	*03:01:01	SSO,SBT,SSP
4691	Ajlan,Abdula	*04:04:23	*09:01					*02	*03				SSO
8038	Cao,Kai	*04:04:01	*09:01:21	*01:01/03/06		*03:01	*03:01/02/03	*02:02:01	*03:02:01	*01:03	*02:01	*03:01/*+	SSO,SBT
774	Cecka,J.Mich	*04:04/118+	*09:01/11+	*01:01	*01:03	*03		*02:02/06+	*03:02/32+	*01:03	*02:01/*+	*03:01	SSP, SSO
8070	Chang, Uckjin	*04	*09										P-SSP
9916	Charlton,Ron	*04:04:01	*09:01:02/21	*01:01:01:01+	*01:03			*02:02/12	*03:02/106+				SSP,SBT
4492	Charron,D.	*04:04/118+	*09:01/18+	*01:01	*01:03	*03:01	*03:01/02/03	*02:02/12	*03:02/85+	*01:03	*02:01	*03:01/*+	P-SSO,SSP
8021	Clark,Brendan	*04:04	*09:01	*01				*02:02	*03:02		*02:01	*03:01	P-SSP,RVSSO
3632	Colombe,Beth	*04:04	*09:01	*01:01	*01:03	*03:01	*03:03	*02:02	*03:02				SSOP,SSP
5130	Costeas,Paul	*04:04	*09:01/04	*01:01/*03:01	*01:03	*03:01	*03:03	*02:02	*03:02				SSO,SSP
779	Daniel,Claud	*04	*09	*01:01/03+		*03:01	*03:03	*02	*03:02	*01:03	*02:01	*03:01	P-SSP,SSO
5219	Daniel,Dolly	*04	*09					*02	*03				
3766	Dunn,Paul	*04	*09	*01		*03		*02	*03	*01	*02:01	*03:01	RT-PCR,SSO,SSP
5214	Eckels/CPMC	*04	*09	*01	*01	*03:01	*03	*02	*03 (DQ8)	*01:03	*02:01:02G	*03:01P	SSOP
3135	Enczmann,J	*04:04	*09:01	*01:01	*01:03			*02:02	*03:02		*02:01	*03:01	SBT,P-SSP,P-SSO
762	Fischer,Got	*04:04	*09:01/12+	*01:01/06	*01:03	*03:01	*03:03	*02:02	*03:02		*02:01	*03:01/*+	SSO,SSP,SBT
4079	Fort,Maryliss	*04:04/79+	*09:01/21			*03:01	*03:03/01/02	*02:02	*03:02		*02:01	*03:01/*+	SSP,SSO-HD
792	Gandhi,Manis	*04:04	*09:01	*01:01	*01:03	*03:01	*03:03	*02:02	*03:02		*02:01	*03:01	SSO,SSP
8043	Gideoni,Osnat	*04:04	*09:01			*03:01	*03:03	*02:02	*03:02	*01:03	*02:01	*03:01	SSP
9002	Gideoni_LR	*04	*09					*02	*03				SSO
910	Hahn,Amy B.	*04	*09	*+		*03:01	*03:03	*02	*03:02				SSP
810	Hamdi,Nuha	*04:04/23+	*09:01/04+			*03:01	*03:01/02/03	*02:02/12	*03:02/85+				SSO
2344	Hurley/Hartz	*04:04:01	*09:01:02G			*03:01:01	*03:03:01	*02:01:01G	*03:02:01G	*01:03:01G	*02:01:02G	*03:01:01G	
771	Israel,Shosh	*04:04	*09:01					*02:02	*03:02				
9003	Israel_LR	*04	*09					*02	*03				SSO
794	Jaatinen,Tai	*04:04	*09:01	*01:01/*03:01N	*01:03	*03:01/02/03		*02:02	*03:02	*01:03	*02:01/*+	*03:01/*+	SBT,SSO,SSP
5891	Jiang,Yueqin	NT											P-SBT
2847	Kihara,Masaaki	*04	*09										rSSO
4337	Kim,Tai-Gyu	*04:04	*09:01					*02:02	*03:02		*02:01	*03:01	SBT,SSP
1694	Kissel&Hess	*04	*09	*+				*02:02	*03:02				SSP
168	Klein,Tirza	*04:04	*09:01					*02:02	*03:02				P-SSO,SSP
9000	Klein_LR	*04	*09					*02	*03				
87	Land,Geoffre	*04:04	*09:01	*01:01	*01:03	*03:01	*03:03	*02:02	*03:02		*02:01	*03:01	SBT,SSO,SSP
725	Lardy,N.M.	*04	*09	*+		*03		*02	*03				SSO, SSP
278	Lee,Jar-How	*04:04	*09:01	*01:01	*01:03	*03:01	*03:03	*02:02	*03:02	*01:03	*02:01	*03:01	SSP,RVSSOP
6649	Lim,Young Ae	*04	*09	*+	*+								SSP
274	Lo,Raymundo	*04	*09			*03:01	*03	*02:02	*03:02	*01:03	*02:01	*03:01	SSO
731	Loewenthal,R	*04:04:01	*09:01:02					*02:02	*03:02:01				SBT,SSO
759	Lopez-Cepero	*04:04/23+	*09:01/04+	*01:01/03+		*03:01/02/03		*02:02/12	*03:02/85	*01:03	*02:01P	*03:01P	RVSSO
8052	Marcos,Cintia Y	*04	*09			*03:01	*03:01/02/03	*02:02/12	*03:02/85+				P-SSO
206	McAlack-Hana	*04	*09	*01		*03	*03	*02	*03 (DQ8)				RVSSOP
8042	Muncher,Lior	*04:04	*09:01	*01:01	*01:03			*02:02	*03:02				SSO,SSP
9001	Muncher_LR	*04	*09	*01				*02	*03				SSO,SSP
54	Pancoska,Ca	*04	*09	*01		*03:01	*03	*02	*03 (DQ8)	*01:03	*02:01	*03:01	RVSSO
3966	Permpikul&Ve	*04:04	*09:01	*01:01	*01:03			*02:02	*03:02				P-SSP
2400	Phelan,Donna	*04:04	*09:01/21	*01		*03:01:01G		*02:02	*03:02		*02:01	*03:01/*+	SSO,SBT,SSP
8001	Rao,Prakash	*04:04	*09:01	*01:01	*01:03	*03		*02:02	*03:02		*02:01	*03:01/*+	RVSSO,SSP
3753	Reed,Elaine	*04:04	*09:01/21	*01:01/03+	*01:01/03+	*03:01	*03:01/02/03	*02:02	*03:02				SBT,SSO

Table 5: Individual laboratory results for B-cell #510-Class II

Center	Investigator	DRB1		DRB4	DRB4	DQA1		DQB1		DPA1	DPB1		METHOD
3519	Renac, Virginie	*04:04	*09:01/21	*01:01/01N	*01:03	*03:01	*03:03	*02:02	*03:02		*02:01	*03:01	SBT,P-SSP
3519	Renac, Virginie_LR	*04	*09					*02	*03		*02:01	*03:01	SSP
1160	Rosen-Bronson	*04	*09	*01				*02	*03				SSO
793	Rubocki, Rona	*04	*09	*+		*03		*02	*03 (DQ8)		*02:01	*03:01	SSP
4251	Schiller, J	*04:04	*09:01:02G	*01:01/03+	*01:01/03+	*03	*03	*02:02	*03:02	*01	*02:01:02G	*03:01:01G	P-RVSSO, SBT
8068	Shanmugam, He	*04	*09	*+				*02	*03				P-SSP
1108	Sutherland, L	*04	*09	*01	*01	*03	*03	*02	*03				SSOP
5451	Tilanus, Marc	*04:04:01	*09:01:02	*+				*02	*03				SBT, SSP
5462	Turner, E.V.	*04:04	*09:01/21	*01:01/*03:01N	*01:03			*02:02/12+	*03:02/106		*02:01	*03:01P	SSP, SSO, SBT
5642	Varnavidou-N	*04:04	*09:01/02+	*+				*02:02	*03:02				P-SSP
3511	Zeevi, Adrian	*04:04	*09:01	*01:01	*01:03		*03:03	*02:02	*03:02		*02:01	*03:01	RVSSOP, SSP

CTR	DIRNAME	DR4	DR9	DR53				DQ2	DQ8	OTH1
4492	Charron, D	+	+	+				+	DQ3	
910	Hahn, Amy B.	+	+	+				+	+	
54	Pancoska, Car	+	+	+				+	+	
793	Rubocki, Rona	+	+	+				+	+	

Table 6: Individual laboratory results for B-cell #510-Class I

Center	Investigator	HLA-A		HLA-B		HLA-C		METHOD
5488	Adams, Sharon	*24:02	*33:03:01	*15:07:01	*15:16:01	*03	*14	SSO,SBT,SSP
4691	Ajlan,Abdula	*24	*33	*15	*15	*03	*14	SSO
8038	Cao,Kai	*24:02	*33:03:01	*15:07:01	*15:16:01	*03:03/227	*14:02:01	SSO,SBT
774	Cecka,J.Mich	*24	*33	*15:07/126	*15:16/254	*03	*14	SSP,SSO
9916	Charlton,Ron	*24:02	*33:03:01	*15:07:01	*15:16:01	*03:03:01	*14:02:01	SSP,SBT
4492	Charron,D.	*24:02/154/193/195+	*33:03/56/57/60/70+	*15:07/207	*15:16/254	*03:03/189N/192+	*14:02/23/31/50+	P-SSO,SSP
8021	Clark,Brendan	*24:02+	*33:01+	*15:07+	*15:16+	*03:03+	*14:02+	P-SSP,RVSSO
3632	Colombe,Beth	*24	*33	*15	*15	*03	*14	SSOP,SSP
5130	Costeas,Paul	*24:02/35	*33:03	*15:07	*15:16	*03:03	*14:02	SSO,SSP
779	Daniel,Claud	*24	*33	*15:07/126/207	*15:16/67/95/254	*03:03	*14	P-SSP,SSO
5219	Daniel,Dolly	*24	*33	*15	*15	*03	*14	
3766	Dunn,Paul	*24	*33	*15:07/126/207	*15:16/67/95/254	*03	*14	RT-PCR,SSO,SSP
5214	Eckels/CPMC	*24	*33	*15 (B62)	*15 (B63)	*03 (Cw9)	*14	SSOP
3135	Enczmann,J	*24:02	*33:03	*15:07	*15:16	*03:03	*14:02	SBT,P-SSP,P-SSO
792	Gandhi,Manis	*24:02	*33:03	*15:07	*15:16	*03:03	*14:02	SSO,SSP
810	Hamdi,Nuha	*24:02/02Q/05/09N+	*33:01/03/03Q/04+	*15:07/126/207	*15:16/67/95/254	*03:03/62/150/158+	*14:02/23/31/37+	SSO
2344	Hurley/Hartz	*24:02:01:01+	*33:03:01	*15:07:01	*15:16:01	*03:03:01	*14:02:01	
794	Jaatinen,Tai	*24:02	*33:03	*15:07	*15:16	*03:03	*14:02	SBT,SSO,SSP
5891	Jiang,Yueqin	NT						P-SBT
2847	Kihara,Masaaki	*24	*33	*15	*15	*03	*14	RVSSO
4337	Kim,Tai-Gyu	*24:02	*33:03	*15:07	*15:16	*03:03	*14:02	SBT,SSP
1694	Kissel&Hess	*24	*33	*15	*15	*03	*14	SSP
278	Lee,Jar-How	*24:02	*33:03	*15:07	*15:16	*03:03	*14:02	SSP,RVSSOP
274	Lo,Raymundo	*24	*33	*15	*15	*03	*14	SSO
8029	Mani,Rama							SSO
8052	Marcos,Cintia Y	*24	*33	*15:07/126/207	*15:16/67/95/254	*03	*14	P-SSO
206	McAlack-Hana	*24	*33	*15 (B62)	*15 (B63)	*03 (Cw9)	*14	RVSSOP
8042	Muncher,Lior	*24:02	*33:03	*15:07	*15:16	*03:03	*14:02	SSO,SSP
9001	Muncher_LR	*24	*33	*15		*03	*14	SSO,SSP
54	Pancoska,Ca	*24	*33	*15 (B62)	*15 (B63)	*03 (Cw9)	*14	RVSSO
3966	Permpikul&Ve	*24	*33	*15	*15	*03	*14	P-SSP
2400	Phelan,Donna	*24:02	*33:03	*15:07	*15:16	*03:03/20N/227	*14:02	SSO,SBT,SSP
3753	Reed,Elaine	*24:02/03/34/67	*03:03/10/11/53	*15:07	*15:16	*03:03/20N/43/49+	*14:02/06/20/55	SBT,SSO
3519	Renac,Virginie	*24:02	*33:03	*15:07	*15:16	*03:03	*14:02	SBT,P-SSP
3519	Renac,Virginie_LR	*24	*33	*15	*15	*03	*14	P-SSP
4251	Schiller,J	*24:02	*33:03	*15:07	*15:16	*03:03:01G	*14:02	P-RVSSO,SBT
8068	Shanmugam,He	*24	*33	*15	*15	*03	*14	P-SSP
1108	Sutherland,L	*24	*33	*15	*15	*03	*14	SSOP
5462	Turner,E.V.	*24:02	*33:03	*15:07	*15:16	*03:03	*14:02	SSP,SSO,SBT

Cell Exchange #384

The results for Cell Exchange #384 are summarized in Table 7 and Table 8. Molecular typing results for individual laboratories are listed in Ta-

bles 9 -12 for each sample and individual serology results for each sample are listed in Table 13.

Cell 1533. The consensus type for this Hispanic sample is A*02:01(A2)-A*23(A23)-B*44:03(B44)-B*55:01(B55)-C*03:03(Cw3)-C*04:01(Cw4). The probable associations in this cell are B*44:03-C*04:01 and B*55:01-C*03:03, with respective frequencies of 0.01748 and 0.00727, in Hispanics.

Labs were in complete agreement in the detection of A2 and A23 in this cell. A*02:01 was assigned by 27%. However, the assignment of the second A-locus type remained unresolved, as A*23:01 was assigned by only 4 labs, with one lab assigning A*23:01:01G. A*23:01/17 was reported by another 6 labs, and A*23 was reported by 60%. A*23:17 differs from A*23:01 in exon 5 at codon 283 by a single nucleotide substitution (CAC -> CCC), resulting in an amino acid change from histidine to proline. B44 (100%) and B55 (92%) were the B-locus types, with DNA assigning B*44:03 and B*55:01 each by 33%. C*03:03 (41%) and C*04:01 (27%) were the C-locus types.

Cell 1534. The consensus type for this sample from a donor of mixed Caucasian, Black, and Native American heritage is A*23(A23)-A*29:02(A29)-B*44:03(B44)-B*45:01(B45)-C*06:02(Cw6)-C*16:01. One likely association in this cell is B*44:03-C*16:01, commonly observed across all populations. It ranks as the 5th most common haplotype in Hispanics, with HF=0.03311. B*44:03-C*16:01 was observed in 3 other exchange samples, cells 1101, 1272 (same as 1279, 1344), and cell 1496 (same as 1271, 1302, 1340, 1371, 1434) all from Hispanic donors. The other probable association in this cell, B*45:01-C*06:02, is also observed commonly across all populations, with the highest frequency, HF=0.00985, observed in African American populations.

As in cell 1533, the subtype of A*23 remained unresolved in this sample as a number of labs (n=6) were unable to distinguish A*23:01 from A*23:17. A*23:01 was reported by 5 labs, with 1 lab assigning A*23:01:01G. A*29:02 (33%) was assigned as the second A-locus type. A23 and A29 were reported in complete consensus. Labs had no trouble detecting the 2 splits of B12 in this sample, B44 (100%) and B45 (96%), which were confirmed as B*44:03 (36%) and B*45:01 (39%). C*06:02 (27%) and C*16:01(33%) were the reported C-locus types.

Cell 1535. The consensus type for this Filipino sample is A*11:01(A11)-A*24:02(A24)-B*40:10(B60)-B*48:01-(B48)-C*04:03(Cw4)-C*08:01(Cw8). One likely haplotype in this cell is A*24:02-B*48:01-C*08:01, with HF=0.00624, in Asians. The other probable haplotype is, A*11:01-B*40:10-C*04:03. This rare haplotype is observed exclusively in Asian populations, with HF=0.00001. The A*11:01-B*40:10-C*04:03 haplotype in this cell was also observed in previous exchange samples, cells 991 (same as 1092, 1165), 989 (same as 1091, 1166), 1183, and 1378, all from Filipino donors.

This cell was studied numerous times in the Cell Exchange as cells 1425 (2011), 1282 (2006), 1159 (2003), and 1128 (2002), as correctly noted by Claas and Lopez-Cepero. The assignment of B60 in this cell has improved over the years, from a detection level of 75% in 2006 to 88% in this present typing. B40 was assigned by 3 labs, and B61 was misassigned by 1 lab. B*40:10 was reported by 67%, with 5 labs assigning B*40:10:01. B48 was reported by 96% as the second B-locus type and confirmed as B*48:01 (44%). B*48:01:01 was assigned by 5 labs. Cw4 (28%), Cw403 (8%), and Cw6 (4%) were reported for the antigen encoded by C*04:03 (45%). Cw8 (28%) was assigned as the second C-locus type, with DNA assigning C*08:01(34%).

Cell 1536. The consensus type for this Hispanic sample is A*02:01(A2)-A*24:02(A24)-B*35:20(B35)-B*44:03(B44)-C*04:01(Cw4)-C*16:02. One likely haplotype in this cell is A*24:02-B*35:20-C*04:01, observed exclusively in Hispanics, with HF=0.00051. This rare haplotype was observed in another B*35:20 exchange cell, cell 1375, also from a Hispanic donor. The other probable haplotype is A*02:01-B*44:03-C*16:02. This rare haplotype is observed in Hispanics, with HF=0.00043.

The B35 variant encoded by B*35:20 was present in this cell, with 84% of labs assigning B35 and 1 lab assigning B35V. Askar noted the weak reactivity of this cell with B35 and Bw6 antisera. B*35:20 was reported by 59%, with 4 labs assigning B*35:20:01. B*35:20 has only been observed in 2 other exchange samples, cells 1375 and 1476. B44 was reported in complete consensus as the second B-locus type and confirmed as B*44:03 (34%).

Table 7. Summary of the 384th Cell Exchange (Cell #1533-1536)

DNA typing

Cell 1533		Cell 1534		Cell 1535		Cell 1536	
<u>30 labs</u>	% (n)	<u>31 labs</u>	% (n)	<u>30 labs</u>	% (n)	<u>29 labs</u>	% (n)
A*02:01	27(8)	A*23:01:01G	3 (1)	A*11:01	40(12)	A*02:01	28(8)
A*02:01+	13(4)	A*23:01	13(4)	A*11:01+	3 (1)	A*02:01+	14(4)
A*02	60(18)	A*23:01/17	19(6)	A*11	57(17)	A*02	59(17)
		A*23:01+	7 (2)				
		A*23	58(18)				
A*23:01:01G	3 (1)	A*29:02:01	10(3)	A*24:02	37(11)	A*24:02:01	3 (1)
A*23:01	10(3)	A*29:02	23(7)	A*24:02+	7 (2)	A*24:02	28(8)
A*23:01/17	20(6)	A*29:02+	10(3)	A*24	57(17)	A*24:02+	10(3)
A*23:01+	7 (2)	A*29	58(18)			A*24	59(17)
A*23	60(18)						
<u>30 labs</u>	% (n)	<u>31 labs</u>	% (n)	<u>30 labs</u>	% (n)	<u>29 labs</u>	% (n)
B*44:03:01	10(3)	B*44:03:01	10(3)	B*40:10:01	17(5)	B*35:20:01	14(4)
B*44:03	23(7)	B*44:03	26(8)	B*40:10	50(15)	B*35:20	45(13)
B*44:03+	7(2)	B*44:03+	7 (2)	B*40:10+	3 (1)	B*35:20+	3 (1)
B*44	60(18)	B*44	58(18)	B*40 (B60)	10(3)	B*35	38(11)
				B*40	20(6)		
B*55:01:01	10(3)	B*45:01:01	3 (1)	B*48:01:01	17(5)	B*44:03:01	10(3)
B*55:01	23(7)	B*45:01	36(11)	B*48:01	27(8)	B*44:03	24(7)
B*55:01+	7(2)	B*45:01+	3 (1)	B*48:01+	3 (1)	B*44:03+	7 (2)
B*55	60(18)	B*45	58(18)	B*48	53(16)	B*44	59(17)
<u>29 labs</u>	% (n)	<u>30 labs</u>	% (n)	<u>29 labs</u>	% (n)	<u>28 labs</u>	% (n)
C*03:03:01	3 (1)	C*06:02:01	7 (2)	C*04:03:01	10(3)	C*04:01:01	11(3)
C*03:03:01G	3 (1)	C*06:02:01G	3 (1)	C*04:03	35(10)	C*04:01:01G	4 (1)
C*03:03	35(10)	C*06:02	17(5)	C*04:03/107	7 (2)	C*04:01	11(3)
C*03:03+	10(3)	C*06:02+	17(5)	C*04	48(14)	C*04:01+	18(5)
C*03(Cw9)	10(3)	C*06	57(17)			C*04	57(16)
C*03	38(11)						
C*04:01:01	3 (1)	C*16:01:01	13(4)	C*08:01:01	10(3)	C*16:02:01	11(3)
C*04:01:01G	3 (1)	C*16:01	20(6)	C*08:01:01G	3 (1)	C*16:02:01G	4 (1)
C*04:01	21(6)	C*16:01+	10(3)	C*08:01	21(6)	C*16:02	11(3)
C*04:01+	10(3)	C*16	57(17)	C*08:01+	10(3)	C*16:02+	25(7)
C*04	62(18)			C*08	55(16)	C*16	46(13)
						C*04/16	4 (1)

Table 8: Summary of the 384th Cell Exchange (Cell #1533-1536)

Serological Typing

(Hispanic) Cell 1533	
(26 Samples Typed)	
A2	100.0%
	[100.0%]
A23	100.0%
	[100.0%]
B44	100.0%
	[100.0%]
B55	92.3%
B22	7.7%
	[100.0%]
Cw3	50.0%
Cw9	3.8%
	[53.8%]
Cw4	50.0%
	[50.0%]
Bw4	84.6%
Bw6	84.6%
Others Found	
Cw5	3.8%

(Mixed) Cell 1534	
(26 Samples Typed)	
A23	100.0%
	[100.0%]
A29	100.0%
	[100.0%]
B44	100.0%
	[100.0%]
B45	96.2%
B12	3.8%
	[100.0%]
Cw6	50.0%
	[50.0%]
Bw4	84.6%
Bw6	84.6%
Others Found	
Cw16	3.8%

(Filipino) Cell 1535	
(25 Samples Typed)	
A11	96.0%
A11.1	4.0%
	[100.0%]
A24	100.0%
	[100.0%]
B60	88.0%
B40	12.0%
	[100.0%]
B48	96.0%
Cw4	28.0%
Cw403	8.0%
Cw6	4.0%
	[40%]
Cw8	28.0%
Bw6	84.0%
Others Found	
B61	4.0%

(Hispanic) Cell 1536	
(25 Samples Typed)	
A2	100.0%
	[100.0%]
A24	100.0%
	[100.0%]
B35	80.0%
B35V	4.0%
	[84.0%]
B44	100.0%
	[100.0%]
Cw4	52.0%
	[52.0%]
Bw4	84.0%
Bw6	84.0%
Others Found	
B70	12.0%
B75	8.0%
B45	4.0%
Cw16	4.0%

Table 9. Individual laboratory results for Cell #1533 by DNA

Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*02:01	*23:01/17	*44:03:01	*55:01:01	*03:03	*04:01	RSSO,SBT,SSP
774	Cecka,J.Michael	*02	*23	*44	*55	*03	*04	SSP
8070	Chang,Uckjin	*02	*23	*44	*55	*03	*04	PCR-SSP
4492	Charron,D.	*02	*23	*44	*55	*03:03	*04	PCR-SSP
798	Claas,F.H.J.	*02:01	*23:01/17	*44:03:01	*55:01:01	*03:03:01	*04:01:01	SBT
3632	Colombe,Beth	*02:01	*23:01	*44:03	*55:01	*03:03	*04:01	SSO,SSP
779	Daniel,Claud	*02	*23	*44	*55	*03:03	*04	PCR-SSP,SSO
3766	Dunn,Paul	*02	*23	*44	*55	*03	*04	SSO
5214	Eckels/CPMC	*02	*23	*44	*55	*03 (Cw9)	*04	SSO
762	Fischer,Gottfried	*02	*23	*44	*55	*03	*04	SSO,SSP
4079	Fort,Marylise	*02:01/77/410/411+	*23:01	*44:03	*55:01	*03:03	*04:01	PCR-SSP
9002	Gideoni_LR	*02	*23	*44	*55	*03	*04	SSO
3808	Hogan,Patrick	*02	*23	*44	*55	*03:03	*04	SSP
771	Israel,Shoshana	NT						PCR-SSP
9003	Israel_LR	*02	*23	*44	*55	*03	*04	PCR-SSOP
725	Lardy,N.M.	*02	*23	*44	*55	*03	*04	SSO,SSP
745	Latham, Katy	*02:01	*23:01/17	*44:03:01	*55:01:01	*03:03	*04:01	SSO,SSP,SBT
278	Lee,Jar-How	*02:01/01Q/97/291+	*23:01/54/56/58	*44:03/115/122+	*55:01/55N/59/60	*03:03/62/171+	*04:01/75/79/82+	
6649	Lim,Young Ae	*02	*23	*44	*55			SSP
731	Loewenthal,R	*02:01	*23:01	*44:03	*55:01	*03	*04	SBT,SSO
759	Lopez-Cepero	*02:01/07/09/15N/18+	*23:01/03/05/06/07N+	*44:03/02/13/26+	*55:01/03/15/25/29+	*03:03/11/13/20N+	*04:01/04/05/08+	RSSO
54	Pancoska,Carol	*02	*23	*44	*55	*03 (Cw9)	*04	RSSOP
8001	Rao,Prakash	*02	*23	*44	*55	*03:03	*04	RSSO,SSP
3625	Rees,Tracey	*02:01	*23:01/17	*44:03	*55:01	*03:03	*04:01	PCR-SSP,SBT
1160	Rosen-Bronson	*02	*23	*44	*55	*03	*04	SSO
793	Rubocki,Ronald	*02	*23	*44	*55	*03 (Cw9)	*04	SSP
4251	Schiller,Jennifer	*02:01	*23:01:01G	*44:03	*55:01	*03:03:01G	*04:01:01G	PCR-RSSO,SBT
3545	Scornik,Juan C	*02:01/01L	*23:01/17	*44:03	*55:01	*03:03/20N/227	*04:01/30/82	SSOP,SBT
5462	Turner,E.V.	*02:01	*23:01/17	*44:03	*55:01	*03:03	*04:01	SBT,SSO, SSP
5642	Varnavidou-Nico	*02	*23	*44	*55	*03	*04	PCR-SSP
3186	Watson,Narelle	*02	*23	*44	*55	*03	*04	SSO

Table 10. Individual laboratory results for Cell #1534 by DNA

Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*23:01/17	*29:02:01	*44:03:01	*45:01	*06:02:01/83	*16:01:01	RSSO,SBT,SSP
774	Cecka,J.Michael	*23	*29	*44	*45	*06	*16	SSP
8070	Chang,Uckjin	*23	*29	*44	*45	*06	*16	SSP
4492	Charron,D.	*23	*29	*44	*45	*06	*16	PCR-SSP
798	Claas,F.H.J.	*23:01/17	*29:02:01	*44:03:01	*45:01	*06:02:01	*16:01:01	SBT
3632	Colombe,Beth	*23:01	*29:02	*44:03	*45:01	*06:02	*16:01	SSO,SSP
779	Daniel,Claud	*23	*29	*44	*45	*06	*16	PCR-SSP,SSO
3766	Dunn,Paul	*23	*29	*44	*45	*06	*16	SSO
5214	Eckels/CPMC	*23	*29	*44	*45	*06	*16	SSO
762	Fischer,Gottfried	*23	*29	*44	*45	*06	*16	SSO,SSP
4079	Fort,Marylise	*23:01	*29:02/51/52/53	*44:03	*45:01	*06:02	*16:01	PCR-SSP
9002	Gideoni_LR	*23	*29	*44	*45	*06	*16	SSO
3808	Hogan,Patrick	*23	*29	*44	*45	*06	*16	SSP
771	Israel,Shoshana	*23:01	*29:02	*44:03	*45:01	*06:02	*16:01	PCR-SSP
9003	Israel_LR	*23	*29	*44	*45	*06	*16	PCR-SSOP
725	Lardy,N.M.	*23	*29	*44	*45	*06	*16	SSO,SSP
745	Latham, Katy	*23:01/17	*29:02:01	*44:03:01	*45:01:01	*06:02:01	*16:01:01	SSO,SSP,SBT
278	Lee,Jar-How	*23:01/54/56/58	*29:02/26/40/43/44+	*44:03/94/115/122+	*45:01	*06:02/46N/83/104/110	*16:01/39/58/59	
6649	Lim,Young Ae	*23	*29	*44	*45			SSP
731	Loewenthal,R	*23:01	*29:02	*44:03	*45:01	*06:02	*16:01:01	SBT,SSO
759	Lopez-Cepero	*23:01/03/04/05+	*29:01/02/03/04/06+	*44:03/13/26/30/32+	*45:01/03/04/07/11+	*06:02/10/11/12/13+	*16:01/02/07/08/09+	RSSO
54	Pancoska,Carol	*23	*29	*44	*45	*06	*16	RSSOP
8001	Rao,Prakash	*23	*29	*44	*45	*06	*16	RSSO,SSP
3625	Rees,Tracey	*23:01/17	*29:02	*44:03	*45:01	*06:02/83	*16:01/58	PCR-SSP,SBT
1160	Rosen-Bronson	*23	*29	*44	*45	*06	*16	SSO
793	Rubocki,Ronald	*23	*29	*44	*45	*06	*16	SSP
4251	Schiller,Jennifer	*23:01:01G	*29:02	*44:03	*45:01	*06:02:01G	*16:01	PCR-RSSO,SBT
3545	Scornik,Juan C	*23:01/17	*29:02	*44:03	*45:01	*06:02/83	*16:01	SSOP,SBT
5462	Turner,E.V.	*23:01/17	*29:02	*44:03	*45:01	*06:02	*16:01	SBT,SSO, SSP
5642	Varnavidou-Nico	*23	*29	*44	*45	*06	*16	PCR-SSP
3186	Watson,Narelle	*23	*29	*44	*45	*06	*16	SSO

Table 11. Individual laboratory results for Cell #1535 by DNA

Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*11:01	*24:02	*40:10:01	*48:01:01	*04:03:01	*08:01:01	RSSO,SBT,SSP
774	Cecka,J.Michael	*11	*24	*40:10	*48	*04:03	*08	SSP
8070	Chang,Uckjin	*11	*24	*40	*48	*04	*08	SSP
4492	Charron,D.	*11	*24	*40	*48	*04	*08	PCR-SSP
798	Claas,F.H.J.	*11:01	*24:02	*40:10:01	*48:01:01	*04:03:01	*08:01:01	SBT
3632	Colombe,Beth	*11:01	*24:02	*40:10	*48:01	*04:03	*08:01	SSO,SSP
779	Daniel,Claud	*11	*24	*40:10	*48	*04	*08	PCR-SSP,SSO
3766	Dunn,Paul	*11	*24	*40:10	*48	*04:03/107	*08	SSO
5214	Eckels/CPMC	*11	*24	*40:10	*48	*04	*08	SSO
762	Fischer,Gottfried	*11:01	*24:02	*40:10	*48:01	*04:03	*08:01/22/99/102	SSO,SSP,SBT
4079	Fort,Marylise	NT						PCR-SSP
9002	Gideoni_LR	*11	*24	*40	*48	*04	*08	SSO
3808	Hogan,Patrick	*11	*24	*40:10/72/85/91+	*48	*04	*08	SSP
771	Israel,Shoshana	*11:01	*24:02	*40:10	*48:01	*04:03	*08:01	PCR-SSP
9003	Israel_LR	*11	*24	*40	*48	*04	*08	PCR-SSOP
725	Lardy,N.M.	*11	*24	*40	*48	*04	*08	SSO,SSP
745	Latham, Katy	*11:01	*24:02	*40:10:01	*48:01:01	*04:03:01	*08:01:01	SSO,SSP,SBT
278	Lee,Jar-How	*11:01	*24:02	*40:10	*48:01	*04:03	*08:01	
6649	Lim,Young Ae	*11	*24	*40 (B60)	*48			SSP
731	Loewenthal,R	*11:01	*24:02	*40:10:01	*48:01:01	*04:03	*08:01	SBT,SSO
759	Lopez-Cepero	*11:01/02/03/05/07+	*24:02/05/07/09N+	*40:10	*48:01/09/10/11/12+	*04:03/107	*08:01/08/20/22+	RSSO
54	Pancoska,Carol	*11	*24	*40 (B60)	*48	*04	*08	RSSOP
8001	Rao,Prakash	*11	*24	*40:10	*48	*04	*08	RSSO,SSP
3625	Rees,Tracey	*11:01	*24:02	*40:10	*48:01	*04:03	*08:01	PCR-SSP,SBT
1160	Rosen-Bronson	*11	*24	*40:10	*48	*04	*08	SSO
793	Rubocki,Ronald	*11	*24	*40 (B60)	*48	*04	*08	SSP
4251	Schiller,Jennifer	*11:01	*24:02	*40:10	*48:01	*04:03	*08:01:01G	PCR-RSSO,SBT
3545	Scornik,Juan C	*11:01	*24:02/02L	*40:10	*48:01	*04:03	*08:01/22/99/102	SSOP,SBT
5462	Turner,E.V.	*11:01	*24:02	*40:10	*48:01	*04:03	*08:01	SBT,SSO,SSP
5642	Varnavidou-Nico	*11	*24	*40	*48	*04	*08	PCR-SSP
3186	Watson,Narelle	*11	*24	*40:10:01	*48:01:01	*04	*08	SSO,SBT-B only

Table 12. Individual laboratory results for Cell #1536 by DNA

Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*02:01	*24:02	*35:20:01	*44:03:01	*04:01:01	*16:02:01	RSSO,SBT,SSP
774	Cecka,J.Michael	*02	*24	*35	*44	*04	*16	SSP
8070	Chang,Uckjin	*02	*24	*35	*44	*04	*16	SSP
4492	Charron,D.	*02	*24	*35	*44	*04	*16	PCR-SSP
798	Claas,F.H.J.	*02:01	*24:02	*35:20:01	*44:03:01	*04:01:01	*16:02:01	SBT
3632	Colombe,Beth	*02:01	*24:02	*35:20	*44:03	*04:01	*16:02	SSO,SSP
779	Daniel,Claud	*02	*24	*35:20	*44	*04	*16	PCR-SSP,SSO
3766	Dunn,Paul	*02	*24	*35:20	*44	*04	*16:02+	SSO
5214	Eckels/CPMC	*02	*24	*35:20	*44	*04	*16	SSO
762	Fischer,Gottfried	*02:01/02L	*24:02	*35:20	*44:03	*04:01/09N/30/82	*16:02/63	SSO,SSP,SBT
4079	Fort,Marylise	NT						PCR-SSP
9002	Gideon LR	*02	*24	*35	*44	*04	*16	SSO
3808	Hogan,Patrick	*02	*24	*35:20/82/83/85+	*44	*04	*16:02/09/12/19+	SSP
9003	Israel_LR	*02	*24	*35	*44	*04	*16	PCR-SSOP
725	Lardy,N.M.	*02	*24	*35	*44	*04	*16	SSO,SSP
745	Latham, Katy	*02:01	*24:02	*35:20:01	*44:03:01	*04:01:01	*16:02:01	SSO,SSP,SBT
278	Lee, Jar-How	*02:01/01Q/97/291+	*24:02/02Q/135+	*35:20	*44:03/115/122/125+	*04:01/82/144/161/165	*16:02/63	
6649	Lim, Young Ae	*02	*24	*35	*44			SSP
731	Loewenthal,R	*02:01	*24:02:01	*35:20:01	*44:03	*04:01:01/10/33	*16:02:01/25/46	SBT,SSO
759	Lopez-Cepero	*02:01/04/07/09/12+	*24:02/03/09N/11N+	*35:20	*44:03/02/13/26/35+	*04:01/05/09N/10/12+	*16:02/09/12/25/37+	RSSO
54	Pancoska,Carol	*02	*24	*35:20	*44	*04	*16	RSSOP
8001	Rao,Prakash	*02	*24	*35	*44	*04	*16	RSSO,SSP
3625	Rees,Tracey	*02:01	*24:02	*35:20	*44:03	*04:01	*16:02	PCR-SSP,SBT
1160	Rosen-Bronson	*02	*24	*35:20	*44	*04	*16	SSO
793	Rubocki,Ronald	*02	*24	*35	*44	*04	*16	SSP
4251	Schiller,Jennifer	*02:01	*24:02	*35:20	*44:03	*04:01:01G	*16:02:01G	PCR-RSSO,SBT
3545	Scornik,Juan C	*02:01/01L	*24:02/02L	*35:20	*44:03	*04:01/30/41/82	*16:02/63	SSOP,SBT
5462	Turner,E.V.	*02:01	*24:02	*35:20	*44:03	*04:01	*16:02	SBT,SSO,SSP
5642	Varnavidou-Nico	*02	*24	*35	*44	*04	*04/*16	PCR-SSP
3186	Watson,Narelle	*02	*24	*35	*44	*04	*16	SSO

Table 13. Individual laboratory results for Cell #1533-1536 by serology

Investigator	Days Old	Cell No 1533 (Hispanic)										Cell No 1534 (Mixed)								Cell No 1535 (Filipino)								Cell No 1536 (Hispanic)											
		Viab %	A2	A23	B44	B55	Cw3	Cw4	Bw4	Bw6	OTHERS	Viab %	A23	A29	B44	B45	Cw6	Bw4	Bw6	OTHERS	Viab %	A11	A24	B60	B48	Cw4	Cw8	Bw6	OTHERS	Viab %	A2	A24	B35	B44	Cw4	Bw4	Bw6	OTHERS	
Alonso, Anton																																							
Alvarez, Carr		90	+	+	+	+			+	+						+	+				90	+	+	+	+			+											
Askar, Medhat	2	95	+	+	+	B22	+	+	+	+					+	+	+				95	+	+	+	+		+												
Cecka, J. Mic		>95	+	+	+	+										+	+				>95	+	+	+	+			+											
Charron, Domi		85	+	+	+	+															95	+	+	+	+														
Claas, F.H.J.	6	90	+	+	+	+	+	+	+	+						+	+				90	+	+	+	+	w403	+												
Dunn, Paul		95	+	+	+	+										+	+				95	+	+	+	+		+												
Enczmann, J		99	+	+	+	+															99	+	+	+	+														
Esteves Kondo																																							
Fort, Marylis	3	97	+	+	+	+										+	+				97	+	+	+	+														
Gideoni, Osna																																							
Hahn, Amy B.	9	99	+	+	+	+	+									+	+				99	+	+	+	+	+		+	Cw6>										
Hesse, Kissel	6	85	+	+	+	+	+	+	+	+						+	+				85	+	+	+	+	+	+	+											
Hogan, Patric		60	+	+	+	+	+	+	+	+						+	+				60	+	+	+	+	+	+	+											
Israel, Shosh																																							
Klein, Tirza																																							
Kvam, Vonnett		97	+	+	+	+	+	+	+	+						+	+				97	+	+	+	+	w403	+												
Latham, Katy		90	+	+	+	+															95	+	+	+	+														
Loewenthal MD		90	+	+	+	+	+	+	+	+						+	+				90	+	+	+	+		+												
Mah, Helen	2	98	+	+	+	+	+	+	+	+						+	+				98	+	+	+	+	+	+	+											
Meyer, Pieter																																							
Norin, Allen		99	+	+	+	+										+	+				99	+	+	+	+		+												
Pancoska, Car	2	98	+	+	+	+	w9	+								+					98	+	+	+	+		+												
Permpikul, Ve	6	90	+	+	+	+										+	+				90	+	+	+	+		+												
Pollack, Mari																																							
Rees, Tracey	3	95	+	+	+	+	+	+	+	+						+	+				95	+	+	+	+	+	+	+											
Renac, Virgin	3	99	+	+	+	B22										+	+				99	+	+	+	+			+											
Rosen-Bronson		99	+	+	+	+	+	+	+	+						+	+				99	+	+	+	+	+	+	+											
Rubocki, Rona		95	+	+	+	+	+	+	+	+						+	+				95	+	+	+	+		+												
Shai, Isaac	8	90	+	+	+	+	+	+	+	+	Cw5					+	+				92	+	+	+	+	+	+	+											
Tiercy, Jean-																																							
Varnavidou-Ni	7	98	+	+	+	+										+	+				98	+	+	+	+		+												
Vidan-Jeras,	6	90	+	+	+	+	+	+	+	+						+	+				100	+	+	+	+		+												
Watson, Narel	8	40	+	+	+	+										+	+				50	+	+	+	+		+												

Serum Exchange #542

The results for Serum Exchange #542 (sera 1161 -1164), are summarized in Tables 14-20 and individual laboratory results by method are listed

in Tables 21-30. Sera strongly positive to 5C specificities were examined in this study.

Sample 1161 was found to be positive to B62 by all methods. Reactivity to other 5C specificities, as well as to B13, B38, and B56 was also detected by Antiglobulin, Luminex, and ELISA. Additional reactivity to C locus antigens (Cw6, Cw10, Cw17, and Cw18), was also reported by Luminex. Only

3 out of 21 Luminex labs reported class II reactivity for this sample. Among those labs, anti-DR8, -DQ4, and -DQ7 reactivity was reported, along with reactivity to a number of DP antigens.

1161	method	#labs	B62	B75	B72	B51	B57	B63	B56	B13	B49	B50	B52	B71	B35	B68	B38	B53	B78	B46	B55	B37	B18	B76	B77	B44	B45	B41	B27	B39	B15	B67	B42	B60	B61	B47	B48	B59	Cw17	Cw18	Cw10	Cw6		
	NIH-Std	6	33	33		17																								17														
	NIH-Ext	2	50		50																																							
	AHG	4	100	25	25	25	75	75	50	25	25	25	50	25	25	25	25	25	25											25														
	Luminex	29	97	97	97	83	100	97	93	93	90	93	86	90	100	83	66	100	79	86	83	79	69	93	93	69	72	66	66	45		72	59	59	59	55	55	55	66	52	48	48		
	ELISA	2	100	100	100	100	100	100	50	100	100	100	100	100	50	50	50	100	100	100	50	50	50			50	50	50																
	Flow	1	no consensus																																									
	C1q	1	no consensus																																									
	Other	3	100	100	67	67	67	100	67	67	67	67	67	67	67	67	33	67	67	67	33	33	67	100				33	33															

1161	method	#labs	DP10	DP13	DP15	DP17	DP18	DPW3	DPW5	DQ7	DR8	DQ4
	NIH-Std	1	no antigens assigned									
	Luminex	21	14	14	14	14	14	14	14	14	14	14
	C1q	1	no antigens assigned									
	Other	2	no antigens assigned									

For **sample 1162**, reactivity to A2 was reported by all methods. Anti-B57 and -B62 reactivity was also reported by various methods. Additional reactivity to a number of 5C specificities, as well as to A23, A24, A25, A32, A69, 7C and 8C specificities was reported by Luminex and ELISA. Moderate reactivity to C-locus antigens (Cw8, Cw9, Cw10) was also reported by Luminex. Strong class II reactivity to a number of DR antigens (DR7, DR8, DR9, DR11, DR12, DR13, DR14) was detected by Luminex. In addition, moderate reactivity to DQ and DP antigens was also reported by Luminex.

1162	method	#labs	A2	B57	B62	B63	B13	B51	A24	A23	B72	B52	B58	B71	B18	B59	B37	B38	A69	A32	A25	B44	B46	B61	B65	B64	B53	B75	B77	B76	B27	B39	B49	B50	Cw8	Cw9	Cw10	B47	B67	B78	B56	A2C			
	NIH-Std	6	33																																										
	NIH-Ext	2	50	50	50																																								
	AHG	4	100	100	75	50	25	25	25		25																																		
	Luminex	29	100	100	100	100	100	72	83	69	83	76	93	72	83	100	90	83	79	79	62	55	79	66	62	59	48	97	93	93	86	48	76	55	52	72	69	66	66	52	48				
	ELISA	2	100	100	50	100	50	50	50	100		50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50																		
	Flow	1	no consensus																																										
	C1q	1	no consensus																																										
	Other	3	67	100	100	100	67	67	67	67	67	67	67	67	67	67	67	67	67	33	67	33	33						100	100	67	67	67											33	

1162	method	#labs	DR11	DR12	DR13	DR14	DR7	DR8	DR9	DR17	DR18	DR52	DQ7	DQ8	DQ9	DP18	DQ2	DR4	DPW2	DP10	DPw4	DR53	DQ4	DP402	DQ3	DR3
	NIH-Std	1	no consensus																							
	Luminex	21	95	95	95	95	95	95	95	76	76	86	76	76	76	76	76	76	71	61	52	48	33	24	19	19
	C1q	1	no consensus																							
	Other	2	100	100	100	100	100	100	100	100	100	100	100	100	100											

1163	method	#labs	B35	B49	B50	B53	B62	B71	B72	B44	B45	B51	B63	B75	B41	B56	B55	B60	B61	B13	B52	B78	B57	B58	B47
	NIH-Std	6	83	50	33	17	50	17					17	33	17										
	NIH-Ext	2	100	100	100	50	100	100	100	100	50	50		50											
	AHG	4	100	75	75	75	75	50	75	75	75	50	50		75	50	50	25	25	75	50	50	50	25	25
	Luminex	29	100	93	100	96	93	89	96	100	100	93	96	96	100	100	86	96	96	93	89	86	93	93	93
	ELISA	2	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
	Flow	1	no consensus																						
	C1q	1	no consensus																						
	Other	2	50	50	50	50	50									50	50								

Sample 1163 was reported to be strongly positive to 5C specificities by all methods. Additional reactivity to B44 and B45 was reported by various methods. Anti-globulin, Luminex, and ELISA also detected positivity to a number of 7C specificities. In addition, anti-DR17 and -DR18 reactivity was reported by Luminex, along with moderate reactivity to DR13, DR14, and DR52.

1163	method	#labs	B18	B37	B48	B64	B75	B77	B54	B39	A23	A24	A2	B12	B21	B38	B76	B46	B59	B67	B8	B65	A32	B12C	B5C
	NIH-Std	6								33				17	17	17									
	NIH-Ext	2																							
	AHG	4	50		25	25	25						25	25	25								25		
	Luminex	29	100	96	75	71	96	86	71	68	71	71				86	89	79	79	71	64	61			
	ELISA	2		100																					
	Flow	1																							
	C1q	1																							
	Other	2						50	50		50	50											50	50	

1163	method	#labs	DR17	DR18	DR13	DR52	DR14	DP11	DPw6	DQ2
	NIH-Std	1	no antigens assigned							
	Luminex	21	81	81	62	62	57	24	19	19
	C1q	1	no antigens assigned							
	Other	2	100	100						

For **sample 1164**, reactivity to a number of 5C specificities (B49, B57, B58, and B63) was reported by all methods. In addition, positivity to other 5C specificities, as well as to A23, A24, A32, and B38 was detected by various methods. Strong reactivity to C-locus antigens was reported by Luminex as well. This sample was found to be negative for class II.

1164	method	#labs					
	NIH-Std	1	no antigens assigned				
	Luminex	21	no antigens assigned				
	C1q	1	no antigens assigned				
	Other	2	no antigens assigned				

1164	method	#labs	B49	B57	B58	B63	B51	B52	B50	A23	A24	A32	B72	B38	B62	B53	A25	B13	B46	B75	A29	B59	B71	B17
	NIH-Std	6	50	50	50	30			17															17
	NIH-Ext	2	50	100	50	100	50			50	50													
	AHG	4	75	100	100	100	50	50					25	25	25									25
	Luminex	29	93	100	100	96	100	89	68	96	100	100	50	93	93	100	86	82	93	93	86	79	68	
	ELISA	2	100	100	100	100	100	50	50	100	100	100	50	100	50	50	100	50	100	50	50	50	50	
	Flow	1	no consensus																					
	C1q	1	no consensus																					
	Other	2	100	100	100	50	50	50		50	50	50			50	50	50							

1164	method	#labs	B73	B77	Cw12	Cw7	Cw1	Cw8	Cw14	Cw16	Cw9	Cw10	B76	A43	B56	A34	B55	B27	Cw15	B67	B78	B8	B21
	NIH-Std	6																					
	NIH-Ext	2																					
	AHG	4																				25	25
	Luminex	29	100	93	93	93	93	93	89	86	82	82	89	79	79	71	68	68	64	46			
	ELISA	2																			50		
	Flow	1																					
	C1q	1																					
	Other	2																					

Table 14. Summary of the 542nd Serum Exchange (Serum #1161-1164) by NIH-Standard and NIH-Extended - class I

Method: NIH-Std											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
6 typing Labs			6 typing Labs			6 typing Labs			6 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B75	33%	100%	A2	33%	100%	B35	83%	55%	B49	50%	100%
B62	33%	57%				B49	50%	100%	B57	50%	100%
B15	17%	100%				B62	50%	86%	B58	50%	67%
B51	17%	33%				B39	33%	100%	B63	33%	100%
						B50	33%	100%	B17	17%	100%
						B75	33%	100%	B50	17%	100%
						A2	17%	100%			
						B12	17%	100%			
						B21	17%	100%			
						B38	17%	100%			
						B41	17%	100%			
						B53	17%	100%			
						B63	17%	100%			
						B71	17%	100%			

Method: NIH-Ext											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B62	50%	100%	B57	50%	100%	B49	100%	100%	B57	100%	100%
B72	50%	100%	B62	50%	100%	B50	100%	100%	B63	100%	100%
			A2	50%	86%	B62	100%	100%	A23	50%	100%
						B71	100%	100%	A24	50%	100%
						B72	100%	100%	B49	50%	100%
						B44	100%	94%	B51	50%	100%
						B35	100%	90%	B58	50%	50%
						B51	50%	100%			
						B53	50%	100%			
						B75	50%	100%			
						B45	50%	67%			

Table 15. Summary of the 542nd Serum Exchange (Serum #1161-1164) by Antiglobulin - class I

*** Serum 1161 ***		
4 typing Labs		
Antigen	Consensus	Inclusion
B62	100%	89%
B57	75%	100%
B63	75%	100%
B52	50%	100%
B56	50%	75%
B13	25%	100%
B15	25%	100%
B49	25%	100%
B50	25%	100%
B71	25%	100%
B72	25%	100%
B75	25%	100%
B78	25%	100%
B35	25%	80%
B58	25%	67%
B51	25%	56%
B38	25%	50%
B53	25%	50%

*** Serum 1162 ***		
4 typing Labs		
Antigen	Consensus	Inclusion
B57	100%	100%
A2	100%	95%
B62	75%	100%
B63	50%	100%
B13	25%	100%
B51	25%	100%
B72	25%	100%
A24	25%	67%
B58	25%	33%

*** Serum 1163 ***		
4 typing Labs		
Antigen	Consensus	Inclusion
B35	100%	100%
B13	75%	100%
B44	75%	100%
B45	75%	100%
B49	75%	100%
B50	75%	100%
B53	75%	100%
B72	75%	100%
B62	75%	90%
B41	50%	100%
B52	50%	100%
B56	50%	100%
B63	50%	100%
B71	50%	100%
B78	50%	100%
B57	50%	90%
B51	50%	89%
B18	50%	86%
B55	50%	86%
A2	25%	100%
B12	25%	100%
B21	25%	100%
B47	25%	100%
B48	25%	100%
B60	25%	100%
B61	25%	100%
B64	25%	100%
B75	25%	100%
A32	25%	67%
B58	25%	67%

*** Serum 1164 ***		
4 typing Labs		
Antigen	Consensus	Inclusion
B57	100%	100%
B63	100%	100%
B58	75%	100%
B49	75%	80%
B52	50%	100%
B51	50%	83%
B17	25%	100%
B21	25%	100%
B72	25%	100%
B38	25%	67%
B62	25%	60%
B8	25%	50%

Table 16. Summary of the 542nd Serum Exchange (Serum #1161-1164) by Other and C1q - class I

Method: Other											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
3 typing Labs			3 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B62	100%	100%	B57	100%	100%	A23	50%	100%	B49	100%	100%
B63	100%	100%	B62	100%	100%	A24	50%	100%	B57	100%	100%
B75	100%	100%	B63	100%	100%	B12C	50%	100%	B58	100%	100%
B77	100%	100%	B75	100%	100%	B35	50%	100%	A23	50%	100%
B13	67%	100%	B77	100%	100%	B49	50%	100%	A24	50%	100%
B35	67%	100%	A2	67%	100%	B50	50%	100%	A25	50%	100%
B46	67%	100%	A23	67%	100%	B53	50%	100%	A32	50%	100%
B49	67%	100%	A24	67%	100%	B54	50%	100%	B13	50%	100%
B50	67%	100%	A32	67%	100%	B55	50%	100%	B51	50%	100%
B51	67%	100%	B13	67%	100%	B56	50%	100%	B52	50%	100%
B52	67%	100%	B51	67%	100%	B5C	50%	100%	B53	50%	100%
B53	67%	100%	B52	67%	100%	B62	50%	100%	B63	50%	100%
B55	67%	100%	B58	67%	100%	B77	50%	100%			
B56	67%	100%	B71	67%	100%						
B57	67%	100%	B72	67%	100%						
B58	67%	100%	B76	67%	100%						
B71	67%	100%	A25	33%	100%						
B72	67%	100%	A2C	33%	100%						
B76	67%	100%	A69	33%	100%						
B78	67%	100%	B18	33%	100%						
B18	33%	100%	B27	33%	100%						
B27	33%	100%	B37	33%	100%						
B37	33%	100%	B38	33%	100%						
B38	33%	100%	B39	33%	100%						
B39	33%	100%	B44	33%	100%						

Method: C1q											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Table 17. Summary of the 542nd Serum Exchange (Serum #1161-1164) by Luminex - class I

*** Serum 1161 ***		
29 typing Labs		
Antigen	Consensus	Inclusion
B35	100%	100%
B53	100%	100%
B57	100%	100%
B62	97%	100%
B63	97%	100%
B72	97%	100%
B75	97%	100%
B13	93%	100%
B50	93%	100%
B56	93%	100%
B76	93%	100%
B77	93%	100%
B49	90%	100%
B71	90%	100%
B52	86%	100%
B46	86%	75%
B58	83%	100%
B55	83%	75%
B51	83%	62%
B37	79%	100%
B78	79%	100%
B45	72%	75%
B67	72%	75%
B18	69%	100%
B44	69%	50%
B27	66%	100%
B41	66%	100%
CW17	66%	60%
B38	66%	50%
B42	59%	100%
B60	59%	100%
B61	59%	100%
B47	55%	100%
B48	55%	100%
B59	55%	100%
CW18	52%	100%
CW10	48%	100%
CW6	48%	100%
B39	45%	100%

*** Serum 1162 ***		
29 typing Labs		
Antigen	Consensus	Inclusion
A2	100%	100%
B13	100%	100%
B57	100%	100%
B62	97%	100%
B63	97%	100%
B75	97%	100%
B58	93%	100%
B76	93%	100%
B77	93%	100%
B37	90%	75%
B27	86%	71%
A24	83%	100%
B18	83%	100%
B72	83%	80%
B38	83%	60%
A69	79%	100%
B46	79%	100%
A32	79%	83%
B52	76%	50%
B49	76%	40%
B71	72%	100%
CW9	72%	100%
B51	72%	75%
A23	69%	100%
CW10	69%	100%
B47	66%	100%
B67	66%	100%
B61	66%	4%
B65	62%	100%
A25	62%	67%
B59	59%	100%
B64	59%	100%
B44	55%	100%
B50	55%	100%
B78	52%	100%
CW8	52%	100%
B39	48%	100%
B53	48%	100%
B56	48%	100%

*** Serum 1163 ***		
28 typing Labs		
Antigen	Consensus	Inclusion
B18	100%	100%
B35	100%	100%
B41	100%	100%
B44	100%	100%
B45	100%	100%
B50	100%	100%
B56	100%	100%
B37	96%	100%
B53	96%	100%
B60	96%	100%
B61	96%	100%
B63	96%	100%
B72	96%	100%
B75	96%	100%
B13	93%	100%
B47	93%	100%
B49	93%	100%
B51	93%	100%
B58	93%	100%
B62	93%	100%
B57	93%	75%
B52	89%	100%
B71	89%	100%
B76	89%	100%
B55	86%	100%
B77	86%	100%
B78	86%	100%
B38	86%	80%
B46	79%	100%
B59	79%	75%
B48	75%	100%
A23	71%	100%
B54	71%	100%
B64	71%	75%
B67	71%	75%
A24	71%	73%
B39	68%	100%
B8	64%	100%
B65	61%	100%

*** Serum 1164 ***		
28 typing Labs		
Antigen	Consensus	Inclusion
A32	100%	100%
B57	100%	100%
B58	100%	100%
B73	100%	100%
A24	100%	82%
B53	100%	80%
B51	96%	100%
B63	96%	100%
A23	96%	71%
B46	93%	100%
B49	93%	100%
B77	93%	100%
CW12	93%	100%
CW7	93%	84%
B38	93%	80%
B62	93%	80%
CW1	93%	79%
CW8	93%	77%
B75	93%	50%
B52	89%	100%
B76	89%	100%
CW14	89%	100%
A25	86%	100%
A29	86%	100%
CW16	86%	73%
CW9	82%	100%
B13	82%	86%
CW10	82%	67%
A43	79%	100%
B56	79%	100%
B59	79%	100%
A34	71%	50%
B50	68%	100%
B55	68%	100%
B71	68%	100%
B27	68%	80%
CW15	64%	100%
B72	50%	100%
B67	46%	100%

Table 18. Summary of the 542nd Serum Exchange (Serum #1161-1164) by Flow Cytometry and Elisa- class I

Method: Flow Cytometry											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
1 typing Labs			1 typing Labs			1 typing Labs			1 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: Elisa											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B13	100%	100%	A2	100%	100%	B13	100%	100%	A23	100%	100%
B46	100%	100%	A23	100%	100%	B35	100%	100%	A24	100%	100%
B49	100%	100%	B57	100%	100%	B37	100%	100%	A25	100%	100%
B50	100%	100%	B63	100%	100%	B41	100%	100%	A32	100%	100%
B51	100%	100%	A24	50%	100%	B44	100%	100%	B38	100%	100%
B52	100%	100%	A25	50%	100%	B45	100%	100%	B46	100%	100%
B53	100%	100%	A32	50%	100%	B47	100%	100%	B49	100%	100%
B57	100%	100%	A69	50%	100%	B49	100%	100%	B51	100%	100%
B62	100%	100%	B13	50%	100%	B50	100%	100%	B57	100%	100%
B63	100%	100%	B18	50%	100%	B51	100%	100%	B58	100%	100%
B71	100%	100%	B37	50%	100%	B52	100%	100%	B63	100%	100%
B72	100%	100%	B38	50%	100%	B53	100%	100%	A29	50%	100%
B75	100%	100%	B44	50%	100%	B55	100%	100%	B13	50%	100%
B78	100%	100%	B46	50%	100%	B56	100%	100%	B50	50%	100%
B18	50%	100%	B51	50%	100%	B57	100%	100%	B52	50%	100%
B35	50%	100%	B52	50%	100%	B58	100%	100%	B53	50%	100%
B37	50%	100%	B53	50%	100%	B60	100%	100%	B59	50%	100%
B38	50%	100%	B58	50%	100%	B61	100%	100%	B62	50%	100%
B41	50%	100%	B59	50%	100%	B62	100%	100%	B71	50%	100%
B44	50%	100%	B61	50%	100%	B63	100%	100%	B72	50%	100%
B45	50%	100%	B62	50%	100%	B63	100%	100%	B75	50%	100%
B55	50%	100%	B64	50%	100%	B71	100%	100%	B78	50%	100%
B56	50%	100%	B65	50%	100%	B72	100%	100%			
B58	50%	100%	B71	50%	100%	B75	100%	100%			
						B78	100%	100%			

Table 19. Summary of the 542nd Serum Exchange (Serum #1161-1164) by Standard, Other and C1q - class II

Method: NIH-Standard											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			no consensus			no antigens assigned			no antigens assigned		

Method: Other											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			DR11	100%	100%	DR17	100%	100%	no antigens assigned		
			DR12	100%	100%	DR18	100%	100%			
			DR13	100%	100%						
			DR14	100%	100%						
			DR17	100%	100%						
			DR18	100%	100%						
			DR52	100%	100%						
			DR7	100%	100%						
			DR8	100%	100%						
			DR9	100%	100%						
			DQ7	50%	100%						
			DQ8	50%	100%						
			DQ9	50%	100%						

Method: C1q											
*** Serum 1161 ***			*** Serum 1162 ***			*** Serum 1163 ***			*** Serum 1164 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			no consensus			no antigens assigned			no antigens assigned		

Table 20. Summary of the 542nd Serum Exchange (Serum #1161-1164) by Luminex - class II

*** Serum 1161 ***		
21 typing Labs		
Antigen	Consensus	Inclusion
DP10	14%	100%
DP13	14%	100%
DP15	14%	100%
DP17	14%	100%
DP18	14%	100%
DPW3	14%	100%
DPW5	14%	100%
DQ7	14%	100%
DR8	14%	100%
DQ4	14%	50%
DP11	10%	100%
DP14	10%	100%
DP9	10%	100%
DPW1	10%	100%
DPW4	10%	100%
DPW6	10%	100%
DQ6	10%	100%
DR14	10%	100%
DR15	10%	100%
DR16	10%	100%
DR52	10%	100%
DQ8	10%	67%
DQ2	10%	60%
DP402	5%	100%
DPW2	5%	100%
DQ5	5%	100%
DQ9	5%	100%
DR11	5%	100%
DR12	5%	100%
DR13	5%	100%
DR17	5%	100%
DR18	5%	100%
DR53	5%	100%
DR4	5%	80%

*** Serum 1162 ***		
21 typing Labs		
Antigen	Consensus	Inclusion
DR11	95%	100%
DR12	95%	100%
DR13	95%	100%
DR14	95%	100%
DR7	95%	100%
DR8	95%	100%
DR9	95%	100%
DR52	86%	100%
DP18	76%	100%
DQ2	76%	100%
DQ7	76%	100%
DQ8	76%	100%
DQ9	76%	100%
DR17	76%	100%
DR18	76%	100%
DR4	76%	100%
DPW2	71%	100%
DP10	62%	100%
DPW4	52%	100%
DR53	48%	75%
DQ4	33%	100%
DP402	24%	100%
DQ3	19%	100%
DR3	19%	100%
DP11	5%	100%
DR16	5%	100%

*** Serum 1163 ***		
21 typing Labs		
Antigen	Consensus	Inclusion
DR17	81%	100%
DR18	81%	100%
DR13	62%	100%
DR52	62%	62%
DR14	57%	100%
DP11	24%	100%
DPW6	19%	100%
DQ2	19%	100%
DR11	14%	100%
DR3	14%	100%
DQ5	10%	100%
DR12	5%	100%
DR8	5%	100%

*** Serum 1164 ***		
21 typing Labs		
Antigen	Consensus	Inclusion
no antigens assigned		

Table 21. Individual laboratory results for Serum #1161-#1164 by NIH-Standard and NIH-Extended

Investigator	**** Serum 1161 ****				**** Serum 1162 ****				**** Serum 1163 ****											**** Serum 1164 ****						Method				
	% POS	B75	B62	Other	% POS	A2		Other	% POS	B35	B49	B62	B39	B50	B75						Other	% POS	B49	B57	B58		B63			Other
Claas, F.H.J.	0				4				42		+	+	+	+							B38	25	+	+	+				B50	STD
Hogan, Patricia	0				0				5	+	+											2			+				STD	
McCluskey, J.	13	+	+		3				38	+		+	+		+							10							STD	
Reed, Elaine I	12	+	+		9	+			57	+	+	+		+	+						B53,B63,B41,	21	+	+	+	+			STD	
Suciu-Foca, N	10			B15	11	+			60	+											A2,B21,B12		+			+		B17	STD	
Watson, Nare	1			B51	1				15	+											B51	10		+					STD	

Investigator	**** Serum 1161 ****				**** Serum 1162 ****				**** Serum 1163 ****											**** Serum 1164 ****						Method				
	% POS	B62	B72	Other	% POS	B57	B62	A2	Other	% POS	B49	B50	B62	B71	B72	B44	B35	B51	B53	B75	B45	Other	% POS	B57	B63		A23	A24	B49	B51
Dunn, Paul	6	+	+		26	+	+	+		34	+	+	+	+	+	+	+	+				30	+	+	+	+		+		EXT
Lardy, N.M.	0				11					57	+	+	+	+	+	+	+		+	+	+		24	+	+			+	+	EXT

Table 22. Individual laboratory results for Serum #1161-#1164 by Antiglobulin and Other

	**** Serum 1161 ****														**** Serum 1162 ****														
Investigator	% POS	B62	B57	B63	B52	B56																			Other	Method			
Cecka, J. Mici	62	+	+	+	+	+																				B78>	B13>	Antiglobulin	
Hahn, Amy B. PhD		+	+	+																									Antiglobulin
Mah, Helen		+	+	+	+	+																				B75	A24	Antiglobulin	
Suciu-Foca, N	12	+																								B15		Antiglobulin	

	**** Serum 1163 ****														**** Serum 1164 ****																
Investigator	% POS	B35	B13	B44	B45	B49	B50	B53	B72	B62	B41	B52	B56	B63	B71	B78	B57	B51	B18	B55									Other	Method	
Cecka, J. Mici	83	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									B60>	B62	Antiglobulin
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+																				Antiglobulin
Mah, Helen		+		+	+	+	+	+	+	+		+	+	+			+		+									B75>	B38>	Antiglobulin	
Suciu-Foca, N	60	+	+																								A2>	B21>	Antiglobulin		

	**** Serum 1161 ****														**** Serum 1162 ****																			
Investigator	% POS	B62	B63	B75	B77	B13	B35	B46	B49	B50	B51	B52	B53	B55	B56	B57	B58	B71	B72	B76	B78											Other	Method	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+																Other	
Reed, Elaine I	82	+	+	+	+														+	+													Other	
Rosen-Bronsc	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+											CW6>	Other

	**** Serum 1163 ****														**** Serum 1164 ****																			
Investigator	% POS	A23	A24	B12C	B35	B49	B50	B53	B54	B55	B56	B5C	B62	B77																		Other	Method	
Phelan, Donn.		+	+	+					+	+	+	+																					A24>	Other
Reed, Elaine I	98				+	+	+	+					+	+																			B63	Other
Rosen-Bronsc																																		Other

Table 24. Individual laboratory results for Serum #1162 by Luminex

Investigator	**** Serum 1162 ****																												Method									
	% POS	A2	B13	B57	B62	B63	B75	B58	B76	B77	B37	B27	A24	B18	B72	B38	A69	B46	A32	B52	B49	B71	CW9	B51	A23	CW10	B47	B67		B61	B65	A25	B59	B64	B44	B50	Other	
Alvarez/Carretto	20	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A29,A2403	LMX	
Brouard, Tabary/Ph	45	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B53,B56,CW1 >	LMX	
Cecka, J. Michael F	51	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B53,B56,B39 >	LMX	
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A203,B78,B53 >	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,BW4,CW8,CW12	LMX	
Esteves Kondo, De	35	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B78,B53,B56 >	LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B53,B56,B39 >	LMX	
Hamdi, Nuha	71%	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B53,B39,CW8 >	LMX	
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,A29	LMX	
Holdsworth, Rhond		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B78,B53,B56 >	LMX	
Klein, Tirza	15	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW3	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Loewenthal , Ron M		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B78,B53,B56 >	LMX
Mani, Rama	76	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B48,B78,B82,B54 >	LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B53,B56,A74 >	LMX
Meyer, Pieter Wa	18	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40,B15,A29	LMX	
Pancoska, Carol Ph	54	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B39,CW8,CW12	LMX	
Permpikul, Vejbaes		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A33,A74,A68	LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B53,B56,CW1,CW8 >	LMX
Reed, Elaine F. Phl		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B53,B56,B39 >	LMX
Rosen-Bronson, Sa	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B53,B56,B39 >	LMX
Suciu-Foca, Nicole		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B53,B56,B39 >	LMX
Terasaki, Paul I. Pl		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW8	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B78,B53,B56 >	LMX

Table 25. Individual laboratory results for Serum #1163 by Luminex

Investigator	% POS	**** Serum 1163 ****																								Other	Method												
		B18	B35	B41	B44	B45	B50	B56	B37	B53	B60	B61	B63	B72	B75	B13	B47	B49	B51	B58	B62	B57	B52	B71	B76			B55	B77	B78	B38	B46	B59	B48	A23	B54	B64	B67	A24
Alvarez/Carretto	40	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,B82,B8,A2403 >	LMX
Brouard, Tabary/Ph	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A203,A2,B40 >	LMX
Cecka, J. Michael F	89	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B39	LMX	
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A203,A2,A34 >	LMX	
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A203,A2,A66 >	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,A69,B65,B39 >	LMX	
Esteves Kondo, De	46	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A34,B39	LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,A34,A68,A69 >	LMX	
Hamdi, Nuha	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,A34,A32,A69 >	LMX		
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,B82,B7,B65 >	LMX		
Holdsworth, Rhond		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A66,A25 >	LMX		
Klein, Tirza	22	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40	LMX		
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Loewenthal , Ron M		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,B42	LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A2,A66,A25 >	LMX	
Mani, Rama	92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,B82 >	LMX		
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A2 >	LMX	
Meyer, Pieter Wa	15	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40,B15	LMX		
Pancoska, Carol Ph	61	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,A34,A69,B65 >	LMX		
Permpikul, Vejbaes		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B39	LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B39,CW10	LMX		
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A34,A69 >	LMX	
Reed, Elaine F. Phl		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A66,A26 >	LMX	
Rosen-Bronson, Sa	92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A34,A69,B65,B39 >	LMX		
Suciu-Foca, Nicole		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A34,A69 >	LMX	
Terasaki, Paul I. Pl		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A34,B39,B8,CW10 >	LMX	
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B39,B7801,B3901	LMX	
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A66,A25 >	LMX	

Table 26. Individual laboratory results for Serum #1164 by Luminex

Investigator	**** Serum 1164 ****																												Other	Method															
	% POS	A32	B57	B58	B73	A24	B63	B51	B63	A23	B46	B49	B77	CW12	CW7	B38	B62	CW1	CW8	B75	B52	B76	CW14	A25	A29	CW16	CW9	B13			CW10	A43	B56	B59	A34	B50	B55	B71	B27						
Alvarez/Carretto	31	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2403	LMX					
Brouard, Tabary/Ph	69	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B7,B67,B72,B8 >	LMX					
Cecka, J. Michael F	67	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX					
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B67,B72,A2403 >	LMX					
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B67,B72,B8 >	LMX				
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW15	LMX				
Esteves Kondo, De	37	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX					
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B67,B72,CW15	LMX				
Hamdi, Nuha	87	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW15	LMX				
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX				
Holdsworth, Rhond		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B7,B67,B72 >	LMX			
Klein, Tirza	18	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW3	LMX				
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX				
Loewenthal , Ron M		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX			
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B61,B78,B82,B7 >	LMX		
Mani, Rama	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,A2,B60 >	LMX			
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B7,B67,B72 >	LMX		
Meyer, Pieter Wa	29	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B15,CW3	LMX		
Pancoska, Carol Ph	47	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B67,B72,CW15	LMX		
Permpikul, Vejbaes		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW15	LMX		
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW15	LMX		
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B67,B72,A2403 >	LMX	
Reed, Elaine F. Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B7,B72,B81,CW15	LMX	
Rosen-Bronson, Sa	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B7,B67,B72 >	LMX	
Suciu-Foca, Nicole		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B67,B72,CW15	LMX	
Terasaki, Paul I. Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW15	LMX	
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2403	LMX	
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B78,B7,B67 >	LMX

Table 27. Individual laboratory results for Serum #1161-#1164 by Elisa, Flow Cytometry, and C1q

		**** Serum 1161 ****																**** Serum 1162 ****						
Investigator	% POS	B13	B46	B49	B50	B51	B52	B53	B57	B62	B63	B71	B72	B75	B78	Other	% POS	A2	A23	B57	B63	Other	Method	
Esteves Kond	44	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B44,B45>	50	+	+	+	+	A24,B61>	Elisa	
Hahn, Amy B.		+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+		Elisa	

		**** Serum 1163 ****																**** Serum 1164 ****																																		
Investigator	% POS	B13	B35	B37	B41	B44	B45	B47	B49	B50	B51	B52	B53	B55	B56	B57	B58	B60	B61	B62	B63	B71	B72	B75	B78	Other	% POS	A23	A24	A25	A32	B38	B46	B49	B51	B57	B58	B63	Other	Method												
Esteves Kond	60	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B48>	38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B62>	Elisa
Hahn, Amy B.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A23		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		Elisa

		**** Serum 1161 ****																**** Serum 1162 ****									
Investigator	% POS																	Other	% POS							Other	Method
Eckels/CPMC	99																		96								FC

		**** Serum 1163 ****																**** Serum 1164 ****													
Investigator	% POS																	Other	% POS											Other	Method
Eckels/CPMC	96																		96												FC

		**** Serum 1161 ****																**** Serum 1162 ****									
Investigator	% POS	B57	B62	B63	B75	B76	B77											Other	% POS	A2	B57	B62	B75	B76	B77	Other	Method
Phelan, Donr		+	+	+	+	+	+													+	+	+	+	+	+		C1q

		**** Serum 1163 ****																**** Serum 1164 ****																									
Investigator	% POS	B13	B35	B41	B45	B49	B50	B51	B52	B53	B61	B62	B71	B72	B75	B78	CW7	Other	% POS	A25	A32	B38	B46	B49	B51	B52	B57	B58	B59	B63	Other	Method											
Phelan, Donr		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B77,Cw1>	C1q

Table 28. Individual laboratory results for Serum #1161-#1164 by NIH-Standard, Other, and C1q - class II

	**** Serum 1161 ****			**** Serum 1162 ****										**** Serum 1163 ****			**** Serum 1164 ****						
Investigator	% POS	no antigens assigned	Other	% POS	DR11										Other	% POS	no antigens assigned	Other	% POS	no antigens assigned	Other	Method	
Reed, Elaine F.	11			30	+											52				18			STD

	**** Serum 1161 ****			**** Serum 1162 ****										**** Serum 1163 ****			**** Serum 1164 ****							
Investigator	% POS	no antigens assigned	Other	% POS	DR11	DR12	DR13	DR14	DR17	DR18	DR52	DR7	DR8	DR9	Other	% POS	DR17	DR18		Other	% POS	no antigens assigned	Other	Method
Phelan, Donna L					+	+	+	+	+	+	+	+	+	+	DQ7,DQ8,DQ9		+	+						Other
Reed, Elaine F.	0			90	+	+	+	+	+	+	+	+	+	+		40	+	+			0			Other

	**** Serum 1161 ****			**** Serum 1162 ****										**** Serum 1163 ****			**** Serum 1164 ****						
Investigator	% POS	no antigens assigned	Other	% POS	DR11										Other	% POS	no antigens assigned	Other	% POS	no antigens assigned	Other	Method	
Phelan, Donna L					+																		C1q

Table 29. Individual laboratory results for Serum #1161-#1162 by Luminex - class II

**** Serum 1161 ****													**** Serum 1162 ****																																
Investigator	% POS	DP10	DP13	DP15	DP17	DP18	DPW3	DPW5	DQ7	DR8	DQ4	Other	Investigator	% POS	DR11	DR12	DR13	DR14	DR7	DR8	DR9	DR52	DP18	DQ2	DQ7	DQ8	DQ9	DR17	DR18	DR4	DPW2	DP10	DPW4	DR53	Other	Method									
Brouard, Tab	0												Brouard, Tab	94	+	+	+	+	+	+	+	+	+	+							+	+	+		+	DR3,DQ3>	LMX								
Cecka, J. Micl	58												Cecka, J. Micl	51	+	+	+	+	+	+	+	+	+			+	+	+	+	+									LMX						
Chen, Dong-F													Chen, Dong-F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	DP402	LMX						
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	DR14,DR15>	Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DR4,DP402	LMX				
Eckels/CPMC													Eckels/CPMC		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		DP402	LMX					
Esteves Kond	29												Esteves Kond	35																									LMX						
Hahn, Amy B.		+	+	+	+	+	+	+	+	+	+	DR53,DPW4>	Hahn, Amy B.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX				
Hamdi, Nuha	97	+	+	+	+	+	+	+	+	+	+	DR4,DR11>	Hamdi, Nuha	94	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4,DP11	LMX			
Hogan, Patric													Hogan, Patric		+	+	+	+	+	+	+	+	+	+	+						+	+			+	+	+	+	+	DR3,DQ3	LMX				
Holdsworth, R	0												Holdsworth, R		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DP402	LMX			
Klein, Tirza	0												Klein, Tirza	41	+	+	+	+	+	+	+	+																		DR3,DQ3	LMX				
Mani, Rama	0												Mani, Rama	90	+	+	+	+	+	+	+	+			+	+	+	+	+	+								+	+	DR16,DQ4	LMX				
Meyer, Pieter	6												Meyer, Pieter	50	+	+	+	+	+	+	+				+															DR3,DQ3	LMX				
Pancoska, Ca	0												Pancoska, Ca	54	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX		
Permpikul, Ve	0												Permpikul, Ve		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX			
Phelan, Donn													Phelan, Donn		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Ramon, Danie													Ramon, Danie		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX		
Reed, Elaine I	0												Reed, Elaine I		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Rosen-Bronsc													Rosen-Bronsc	92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Turner, E.V. F	0												Turner, E.V. F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Vather, Nelso													Vather, Nelso		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	

Table 30. Individual laboratory results for Serum #1163-#1164 by Luminex - class II

**** Serum 1163 ****									**** Serum 1164 ****								
Investigator	% POS	DR17	DR18	DR13	DR52	DR14	DP11	Other	Investigator	% POS					Other	Method	
Brouard, Tab	34	+	+	+	+	+	+	DPW6	Brouard, Tab	0						LMX	
Cecka, J. Micl	89	+	+						Cecka, J. Micl							LMX	
Chen, Dong-F		+	+	+	+	+			Chen, Dong-F							LMX	
Dunn, Paul		+	+	+	+	+	+	DQ2,DQ5,DPW6	Dunn, Paul							LMX	
Eckels/CPMC		+	+		+				Eckels/CPMC							LMX	
Esteves Kond	46								Esteves Kond							LMX	
Hahn, Amy B.		+	+	+	+	+			Hahn, Amy B.							LMX	
Hamdi, Nuha	43	+	+	+	+	+			Hamdi, Nuha	0						LMX	
Hogan, Patrici				+	+	+		DR3	Hogan, Patrici							LMX	
Holdsworth, R		+	+	+	+	+		DR11,DQ2,DPW6	Holdsworth, R	0						LMX	
Klein, Tirza	23							DR3	Klein, Tirza	0						LMX	
Mani, Rama	40	+	+		+				Mani, Rama	0						LMX	
Meyer, Pieter	17			+		+		DR3,DR8,DR11,DR12	Meyer, Pieter	6						LMX	
Pancoska, Ca	11	+	+	+	+		+		Pancoska, Ca	0						LMX	
Permpikul, Ve		+	+	+		+			Permpikul, Ve	0						LMX	
Phelan, Donn		+	+						Phelan, Donn							LMX	
Ramon, Danie		+	+						Ramon, Danie							LMX	
Reed, Elaine I		+	+	+	+	+		DQ2	Reed, Elaine I	0						LMX	
Rosen-Bronsc	22	+	+	+	+	+	+		Rosen-Bronsc	0						LMX	
Turner, E.V. F		+	+						Turner, E.V. F	0						LMX	
Vather, Nelso		+	+	+	+	+	+	DR11,DQ2,DQ5,DPW6	Vather, Nelso							LMX	

Serum Exchange #543

The results for Serum Exchange #543 (sera 1165 -1168), are summarized in Tables 31-36 and individual laboratory results by method are listed

in Tables 37-46. Sera strongly positive to A11 and A1 were examined in this study.

1165	method	#labs	A11	A25	A26	A66	A1	A3	A10	A34	A33	A36	A68	A80	A29	A30	A31	A74	A2	A69	A43	A6601	A6602	A23	A24	2403	A1101	A1102
	NIH-Std	7	100	14	57	57	14	14	14	14	14																	
	NIH-Ext	2	100	50	50	50	50	50				50	50															
	AHG	4	100	75	75	50	75	75	25	75	75	50	50	50	25	50	50	50	25					25				
	Luminex	27	81	100	100	67	96	93		100	100	96	100	93	93	93	100	100	89	100	93	41	33		37	33	26	26
	ELISA	2	100	100	100	100	100	50		100	100	100	100	100	100	100	100	100	100	100								
	Flow	1	no consensus																									
	Other	1	no consensus																									

Sample 1165 was reported to be strongly positive to A11 by all methods. Additional reactivity to other 1C specificities and a number of 10C specificities (A24, A26, A33, A34, A66) was detected by various methods. Anti-A2, -A68, and -A69 reactivity was also reported by various methods.

Reactivity to DR4 was reported by Luminex and 1 lab reporting by NIH-standard. In addition, Luminex detected strong class II reactivity to DQ4, DQ7, DQ8, and DQ9, along with strong reactivity to DR1, DR10, DR13, DR14, DR15, and DR51.

1165	method	#labs	DR4	DR1	DR10	DQ4	DR15	DR14	DQ7	DQ8	DQ9	DR13	DR51	DQ2	DR16	DR17	DR8	DR18	DPW1	DQ3	DQ6	DR9
	NIH-Std	2	50																			
	Luminex	19	100	100	100	95	95	95	89	89	89	89	89	37	27	27	27	21	11	11	11	11
	Flow	1	no consensus																			
	Other	1	no consensus																			

1166	method	#labs	A11	A1	A26	A25	A66	A34	A36	A3	B60	B35	B45	B72	B50	B55	B75	B42	B61	B41	B81	B39	B48	B27	A30	A31	A29	A68	
	NIH-Std	6	100	67	67		17	33																					
	NIH-Ext	2	100	50	50	50	50		50	50																		50	
	AHG	4	100	25	75	75	50	50			25																		
	Luminex	27	81	89	100	100	74	96	96	100	96	100	96	96	93	93	93	93	93	89	89	89	78	69	100	81	81	74	
	ELISA	2	100	50	100	100	100		100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	50	50	100			
	Flow	1	no consensus																										
	Other	1	no consensus																										
1166	method	#labs	A80	A10	B65	B54	B18	A43	B56	B62	B7	B76	B8	A74	B71	A33	B67	B64	B78	B82	A69	A6601	A6602	B2708	B57	A1101	A1102	A24	
	NIH-Std	7		17																									
	NIH-Ext	2																											
	AHG	4	25	25	25																								
	Luminex	27			46		96	93	93	93	93	89	89	85	81	78	78	65	62	54	50	38	35	31	23	27	27	27	
	ELISA	2	100			100																							
	Flow	1																											
	Other	2																											

1166	method	#labs	DR4	DR53	DR9	DR18	DR8	DR10	DR7	DR3
	NIH-Std	2	50							
	Luminex	19	100	84	37	32	32	21	16	11
	Flow	1	no consensus							
	Other	1	no consensus							

For sample 1166, strong reactivity to A11 was reported by all methods. Positivity to A1 and A10 (A25, A26, A34, A66) was also detected by various methods. Additional strong reactivity to B39, B45, B48, 5C, and 7C specificities was reported by Luminex and ELISA. Anti-DR4 positivity was reported by Luminex and 1 lab reporting NIH-standard results. In addition, Luminex reported strong reactivity to DR53, as well as some weak reactivity to a number of other DR antigens.

1167	method	#labs	A1	B57	B58	B63	A3	A23	A24	A30	A11	A80	B55	B27	A36	B42	B54	B56	B7	B44	B45	B81	A25	A26	A66	A29	A43	B76	B82	B67	B75	Cw18	Cw17	A2403	A6601	Cw6	A1101	A1102	B46	B62	B17		
	NIH-Std	6	17	17	17		17																																				
	NIH-Ext	2	100	100	50	50		50																																			
	AHG	4	100	75	50	25	25	25	25	25	25	25	25																														25
	Luminex	26	96	100	96	96	88	100	100	100	85	81	92	100	100	92	92	92	88	85	85	73	77	65	31	62	88	88	85	77	62	62	50	35	27	27	23	23					
	ELISA	2	100	100	50	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	50	100																50	50
	Flow	1	no consensus																																								
	Other	1	no consensus																																								

Sample 1167 was found to be positive to A1, B57, and B58 by all methods. Additional reactivity to B63, A11, 1C and 7C specificities was reported by various methods. Luminex and ELISA also reported strong positivity to B44 and B45. Anti-DR7 and -DR9 reactivity was reported by Luminex and NIH-standard. Strong positivity to DR12, DR53, and a number of DP antigens was also reported by Luminex.

1167	method	#labs	DR7	DR9	DR12	DR53	DP13	DP14	DP17	DPW1	DPW3	DPW5	DP10	DP11	DP15	DP9	DPW6	DR10	DP18	DR52	DPW4	DR14	DR4	DC9
	NIH-Std	2	100	50																				
	Luminex	19	100	100	100	89	83	83	83	83	83	83	78	78	78	78	78	78	78	67	67	17	17	11
	Flow	1	no consensus																					
	Other	1	no consensus																					

1168	method	#labs	A11	A25	A26	A66	A34	A30	A31	A32	A74	A3	A33	A36	A68	A1	A29	A80	A10	A69	B7	B41	B42	B60	B61	B48	B75	B8	
	NIH-Std	6	100	83	83	50	33				17	17							17		17								
	NIH-Ext	2	100	100	100	50	100	50	50	50																			
	AHG	4	75	50	50	50	50	50	50	50	50	75	50	25	50	25	25	25	25									50	
	Luminex	26	81	100	96	73	100	96	100	100	100	96	100	100	96	96	96	85		100	100	100	100	96	73	85	81	100	
	ELISA	2	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100		100	100	100	100	100	100	100	100	100	
	Flow	1	no consensus																										
	Other	1	no consensus																										
1168	method	#labs	B44	B37	B12	A43	B73	B81	Cw18	Cw7	Cw6	Cw9	B67	B38	B39	B77	A6602	A1101	A1102	B18	B49	B13	B27	B50	B57	B46	B55	B63	B64
	NIH-Std	6			17																								
	NIH-Ext	2																											
	AHG	4			25																								
	Luminex	26	42	36		92	92	88	77	77	62	32	73	69	54	46	40	28	28	36	32	28	38	28	28	24	24	24	24
	ELISA	2	100	100																									
	Flow	1																											
	Other	1																											

For **sample 1168**, strong reactivity to A11 and A10 (A25, A26, A34, A66) was detected all methods. Reactivity to a number of 1C and 10C specificities was also reported by various methods. Luminex and ELISA reported additional reactivity to 7C specificities, and Luminex detected reactivity to

some C-locus antigens (Cw6, Cw7, Cw9, Cw18). Luminex and 1 NIH-standard lab reported class II reactivity to DQ3 (DQ7, DQ8, and DQ9). Additional strong reactivity to DR4, DR8, DR11, DR13, DR16, and DQ6 was also reported by Luminex.

1168	method	#labs	DQ7	DQ8	DQ9	DR11	DR4	DR8	DR13	DR16	DQ6	DR15	DQ4	DR53	DR103	DP9	DR14	DPW5	DR12	DR51	DP14	DQ3	DR52
	NIH-Std	2	50	50	50																		
	Luminex	19	89	89	89	100	100	100	94	83	83	56	50	39	25	22	22	17	17	17	11	11	11
	Flow	1	no consensus																				
	Other	1	no consensus																				

Table 31. Summary of the 543rd Serum Exchange (Serum #1165-1168) by NIH-Standard and NIH-Extended - class I

Method: NIH-Std											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
7 typing Labs			6 typing Labs			6 typing Labs			6 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A11	100%	97%	A11	100%	84%	A1	17%	100%	A11	100%	88%
A66	57%	100%	A26	67%	73%	A3	17%	100%	A25	83%	100%
A26	57%	88%	A1	67%	28%	B57	17%	100%	A26	83%	89%
A1	14%	100%	A34	33%	100%	B58	17%	100%	A66	50%	100%
A10	14%	100%	A10	17%	100%				A34	33%	100%
A25	14%	100%	A66	17%	50%				A10	17%	100%
A33	14%	100%							A74	17%	100%
A34	14%	100%							B12	17%	100%
A3	14%	11%							B7	17%	80%
									A3	17%	39%

Method: NIH-Ext											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A11	100%	100%	A11	100%	100%	B57	100%	100%	A25	100%	100%
A26	50%	100%	A25	50%	100%	A1	100%	63%	A34	100%	100%
A36	50%	100%	A26	50%	100%	A23	50%	100%	A11	100%	88%
A66	50%	100%	A66	50%	100%	B58	50%	100%	A26	50%	100%
A25	50%	67%				B63	50%	100%	A31	50%	100%
A3	50%	67%							A32	50%	100%
A68	50%	60%							A66	50%	100%
A1	50%	50%							A30	50%	67%

Table 32. Summary of the 543rd Serum Exchange (Serum #1165-1168) by Antiglobulin and Other - class I

Method: Antiglobulin											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
4 typing Labs			4 typing Labs			4 typing Labs			4 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A11	100%	100%	A11	100%	100%	A1	100%	100%	A11	75%	100%
A1	75%	100%	A25	75%	100%	B57	75%	100%	A3	75%	100%
A25	75%	100%	A26	75%	100%	B58	50%	33%	A25	50%	100%
A26	75%	100%	A34	50%	100%	A11	25%	100%	A26	50%	100%
A34	75%	100%	A66	50%	100%	A23	25%	100%	A34	50%	100%
A33	75%	80%	A1	25%	100%	A24	25%	100%	A66	50%	100%
A3	75%	64%	A10	25%	100%	A3	25%	100%	A68	50%	100%
A66	50%	100%	A80	25%	100%	A30	25%	100%	A74	50%	100%
A68	50%	100%	B60	25%	100%	A80	25%	100%	B8	50%	100%
A80	50%	100%	B65	25%	100%	B17	25%	100%	A30	50%	89%
A31	50%	80%				B55	25%	100%	A31	50%	80%
A36	50%	80%				B63	25%	100%	A33	50%	80%
A74	50%	75%							A32	50%	75%
A30	50%	67%							A1	25%	100%
A10	25%	100%							A10	25%	100%
A2	25%	100%							A29	25%	100%
A23	25%	100%							A36	25%	100%
A29	25%	100%							A80	25%	100%
									B12	25%	100%

Method: Other											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Table 33. Summary of the 543rd Serum Exchange (Serum #1165-1168) by Luminex - class I

*** Serum 1165 ***		
27 typing Labs		
Antigen	Consensus	Inclusion
A25	100%	100%
A26	100%	100%
A31	100%	100%
A33	100%	100%
A34	100%	100%
A68	100%	100%
A69	100%	100%
A74	100%	100%
A1	96%	100%
A36	96%	100%
A29	93%	100%
A3	93%	100%
A43	93%	100%
A80	93%	100%
A30	93%	90%
A2	89%	100%
A11	81%	100%
A66	67%	100%
A6601	41%	100%
A24	37%	50%
A2403	33%	100%
A6602	33%	100%
A1101	26%	100%
A1102	26%	100%

*** Serum 1166 ***		
27 typing Labs		
Antigen	Consensus	Inclusion
A25	100%	100%
A26	100%	100%
B35	100%	100%
A30	100%	93%
A3	100%	67%
A34	96%	100%
A36	96%	100%
B18	96%	100%
B45	96%	100%
B60	96%	100%
B72	96%	100%
A43	93%	100%
B50	93%	100%
B55	93%	100%
B75	93%	83%
B42	93%	80%
B56	93%	80%
B62	93%	80%
B7	93%	60%
B61	93%	57%
B41	89%	100%
B76	89%	100%
B81	89%	100%
B8	89%	83%
B39	89%	75%
A1	89%	55%
A74	85%	80%
A11	81%	100%
A31	81%	100%
B71	81%	100%
A29	81%	64%
A33	78%	100%
B48	78%	75%
B67	78%	75%
A66	74%	100%
A68	74%	100%

*** Serum 1167 ***		
26 typing Labs		
Antigen	Consensus	Inclusion
A30	100%	100%
B57	100%	100%
A23	100%	91%
B27	100%	86%
A24	100%	85%
A36	100%	80%
A1	96%	100%
B58	96%	100%
B63	96%	100%
B42	92%	100%
B54	92%	100%
B55	92%	80%
B56	92%	60%
A3	88%	100%
A43	88%	100%
B7	88%	71%
B76	88%	54%
B82	85%	100%
B44	85%	80%
B45	85%	75%
A11	85%	62%
A80	81%	100%
B67	77%	75%
B81	73%	100%
A26	65%	100%
A29	65%	100%
B75	62%	50%
CW18	62%	100%
CW17	50%	100%
A2403	35%	100%
A66	31%	100%
A6601	27%	100%
CW6	27%	100%
A1101	23%	100%
A1102	23%	100%

*** Serum 1168 ***		
26 typing Labs		
Antigen	Consensus	Inclusion
A25	100%	100%
A31	100%	100%
A32	100%	100%
A33	100%	100%
A34	100%	100%
A36	100%	100%
A69	100%	100%
A74	100%	100%
B41	100%	100%
B42	100%	100%
B7	100%	100%
B8	100%	100%
A26	96%	100%
A29	96%	100%
A3	96%	100%
A30	96%	100%
A68	96%	100%
B60	96%	100%
A1	96%	91%
A43	92%	100%
B73	92%	100%
B81	88%	100%
A80	85%	100%
B48	85%	100%
A11	81%	100%
B75	81%	67%
CW18	77%	100%
CW7	77%	100%
A66	73%	100%
B67	73%	75%
B61	73%	57%
B38	69%	100%
CW6	62%	100%
B39	54%	100%
B77	46%	100%
B44	42%	100%

Table 34. Summary of the 543rd Serum Exchange (Serum #1165-1168) by Flow Cytometry and Elisa - class I

Method: Flow Cytometry											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: Elisa											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A1	100%	100%	A11	100%	100%	A1	100%	100%	A1	100%	100%
A11	100%	100%	A25	100%	100%	A11	100%	100%	A11	100%	100%
A2	100%	100%	A26	100%	100%	A23	100%	100%	A25	100%	100%
A25	100%	100%	A29	100%	100%	A24	100%	100%	A26	100%	100%
A26	100%	100%	A3	100%	100%	A25	100%	100%	A29	100%	100%
A29	100%	100%	A36	100%	100%	A26	100%	100%	A3	100%	100%
A30	100%	100%	A66	100%	100%	A29	100%	100%	A30	100%	100%
A31	100%	100%	A80	100%	100%	A3	100%	100%	A31	100%	100%
A33	100%	100%	B35	100%	100%	A30	100%	100%	A32	100%	100%
A34	100%	100%	B39	100%	100%	A36	100%	100%	A33	100%	100%
A36	100%	100%	B41	100%	100%	A80	100%	100%	A34	100%	100%
A66	100%	100%	B42	100%	100%	B27	100%	100%	A36	100%	100%
A68	100%	100%	B45	100%	100%	B42	100%	100%	A66	100%	100%
A69	100%	100%	B48	100%	100%	B44	100%	100%	A68	100%	100%
A74	100%	100%	B50	100%	100%	B45	100%	100%	A69	100%	100%
A80	100%	100%	B54	100%	100%	B54	100%	100%	A74	100%	100%
A3	50%	100%	B55	100%	100%	B55	100%	100%	A80	100%	100%
			B60	100%	100%	B56	100%	100%	B37	100%	100%
			B61	100%	100%	B57	100%	100%	B41	100%	100%
			B72	100%	100%	B63	100%	100%	B42	100%	100%
			B75	100%	100%	B7	100%	100%	B44	100%	100%
			B81	100%	100%	B81	100%	100%	B48	100%	100%
			B27	100%	50%	A66	50%	100%	B60	100%	100%
			A1	50%	100%	B46	50%	100%	B61	100%	100%
			A30	50%	100%	B58	50%	100%	B7	100%	100%
			A31	50%	100%	B62	50%	100%	B75	100%	100%

Table 35. Summary of the 543rd Serum Exchange (Serum #1165-1168) by NIH-Standard, Other, and Flow Cytometry - class II

Method: NIH-Standard											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DR4	50%	100%	DR4	50%	67%	DR7	100%	100%	DQ7	50%	100%
						DR9	50%	100%	DQ8	50%	100%
									DQ9	50%	100%
									DR14	50%	100%

Method: Other											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
	no consensus			no consensus			no consensus			no consensus	

Method: Flow											
*** Serum 1165 ***			*** Serum 1166 ***			*** Serum 1167 ***			*** Serum 1168 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
	no consensus			no consensus			no consensus			no consensus	

Table 36. Summary of the 543rd Serum Exchange (Serum #1165-1168) by Luminex- class II

*** Serum 1165 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DR1	100%	100%
DR10	100%	100%
DR4	100%	100%
DQ4	95%	75%
DR15	95%	71%
DR14	95%	62%
DQ7	89%	100%
DQ8	89%	100%
DQ9	89%	100%
DR13	68%	100%
DR51	68%	88%
DQ2	37%	20%
DR16	26%	100%
DR17	26%	100%
DR8	26%	100%
DR18	21%	100%
DPW1	11%	100%
DQ3	11%	100%
DQ6	11%	100%
DR9	11%	100%
DP14	5%	100%
DP18	5%	100%
DQ5	5%	100%
DR103	5%	100%
DR11	5%	100%
DR12	5%	100%
DR3	5%	100%
DR53	5%	100%
DR52	5%	80%

*** Serum 1166 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DR4	100%	100%
DR53	84%	100%
DR9	37%	50%
DR18	32%	100%
DR8	32%	67%
DR10	21%	100%
DR7	16%	100%
DR3	11%	100%
DQ4	5%	100%
DQ5	5%	100%
DQ7	5%	100%
DQ8	5%	100%
DR12	5%	100%
DR17	5%	33%

*** Serum 1167 ***		
18 typing Labs		
Antigen	Consensus	Inclusion
DR12	100%	100%
DR7	100%	100%
DR9	100%	100%
DR53	89%	93%
DP13	83%	100%
DP14	83%	100%
DP17	83%	100%
DPW1	83%	100%
DPW5	83%	100%
DPW3	83%	71%
DP10	78%	100%
DP11	78%	100%
DP15	78%	100%
DP9	78%	100%
DPW6	78%	100%
DR10	78%	100%
DP18	78%	83%
DR52	67%	75%
DPW4	67%	50%
DR14	17%	100%
DR4	17%	100%
DQ9	11%	100%
DQ7	6%	100%
DQ8	6%	100%
DR13	6%	100%
DR15	6%	100%
DR18	6%	100%
DR3	6%	100%

*** Serum 1168 ***		
18 typing Labs		
Antigen	Consensus	Inclusion
DR11	100%	100%
DR4	100%	100%
DR8	100%	100%
DR13	94%	50%
DQ7	89%	100%
DQ8	89%	100%
DQ9	89%	100%
DR16	83%	100%
DQ6	83%	57%
DR15	56%	100%
DQ4	50%	57%
DR53	39%	100%
DR103	25%	100%
DP9	22%	100%
DR14	22%	100%
DPW5	17%	100%
DR12	17%	100%
DR51	17%	100%
DP14	11%	100%
DQ3	11%	100%
DR52	11%	100%
DP10	6%	100%
DP15	6%	100%
DP17	6%	100%
DP18	6%	100%
DR10	6%	100%
DR18	6%	100%
DR3	6%	100%
DR7	6%	100%

Table 37. Individual laboratory results for Serum #1165-#1168 by NIH-Standard and NIH-Extended

Investigator	**** Serum 1165 ****							**** Serum 1166 ****					**** Serum 1167 ****						**** Serum 1168 ****							Method					
	% POS	A11	A66	A26			Other	% POS	A11	A26	A1	A34		Other	% POS	A1	B57	B68	A3		Other	% POS	A11	A25	A26		A66	A34		Other	
Claas, F.H.J.	42	+		+				33	+	+	+				21							46	+	+	+				B7	STD	
Fort, Marylise	53	+	+				A33																							STD	
Hogan,Patrick		+	+						+	+													+	+	+	+					STD
McCluskey, J	19	+		+				32	+	+	+	+			0							22	+	+	+						STD
Reed, Elaine I	33	+	+	+			A25,A34	29	+						20		+	+				40	+	+	+	+	+		A74	STD	
Suciu-Foca, N	28	+					A10,A1	22	+		+			A10	22	+			+			20	+						A10,B12	STD	
Watson, Nare	23	+	+	+			A3	24	+	+	+	+		A66	13							32	+	+	+	+	+		A3	STD	

Investigator	**** Serum 1165 ****								**** Serum 1166 ****						**** Serum 1167 ****						**** Serum 1168 ****							Method				
	% POS	A11	A66	A26	A36	A25	A3	Other	% POS	A11	A26	A25	A66		Other	% POS	A1	B57	B68	A23	B63	Other	% POS	A11	A25	A34	A66		A26	A31	Other	
Dunn, Paul	59	+		+		+	+	A68, A1	41	+	+	+				40	+	+		+	+			+	+	+		+	+	A32,A30	EXT	
Lardy, N.M.	33	+	+		+				12	+			+			24	+	+	+				33	+	+	+	+					EXT

STD = NIH-Standard

Ext - NIH-Extended

Table 38. Individual laboratory results for Serum #1165-#1168 by Antiglobulin and Other

**** Serum 1165 ****														**** Serum 1166 ****																		
Investigator	% POS	A11	A1	A25	A26	A34	A33	A3	A66	A68	A80	A31	A36	A74	A30	Other	% POS	A11	A25	A26	A34	A66									Other	Method
Cecka, J. Mici	77	+	+	+	+	+	+	+	+		+	+	+	+	+	A23	32	+	+	+		+									A80	Antiglobulin
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+		A2,A29		+	+	+	+	+								B60	Antiglobulin	
Mah, Helen		+		+	+	+	+			+					+			+	+	+	+								B65	Antiglobulin		
Suciu-Foca, N	20	+	+													A10	15	+											A10,A1	Antiglobulin		

**** Serum 1167 ****														**** Serum 1168 ****																	
Investigator	% POS	A1	B57	B58											Other	% POS	A11	A3	A25	A26	A34	A66	A68	A74	B8	A30	A31	A33	A32	Other	Method
Cecka, J. Mici	30	+	+	+											A80	92	+	+	+	+	+	+	+	+	+	+	+	+	+	A36,A80	Antiglobulin
Hahn, Amy B.		+	+	+											A11,A24,B55,A30 >		+	+	+	+	+	+	+	+	+	+	+	+	+	A29	Antiglobulin
Mah, Helen		+	+												Multi																Antiglobulin
Suciu-Foca, N	20	+													A3,B17		+	+											A10,A1,B12	Antiglobulin	

**** Serum 1165 ****														**** Serum 1166 ****																		
Investigator	% POS	A11	A1	A25	A26	A34	A36	A66							Other	% POS	A11	A25	A26											Other	Method	
Reed, Elaine	96	+	+	+	+	+	+	+								98	+	+	+												Other	Other

**** Serum 1167 ****														**** Serum 1168 ****																		
Investigator	% POS	A11	A23	A24	A26	A30	A36	B57	B58						Other	% POS	A25	A26	A34	A66										Other	Method	
Reed, Elaine	86	+	+	+	+	+	+	+	+							98	+	+	+	+											Other	Other

Table 39. Individual laboratory results for Serum #1165 Luminex

		**** Serum 1165 ****																										
Investigator	% POS	A1	A25	A26	A31	A33	A34	A68	A69	A74	A36	A2	A29	A3	A43	A80	A30	A11	A66	A6601	A24	A2403	A6602	A1101	A1102	Other	Method	
Alvarez/Carretto	26	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+			+	+	+	A203	LMX	
Brouard, Tabary	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+		+	+	+	+	A203	LMX	
Cecka, J. Michael	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Chen, Dong-Fen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+		+	+	+	+	A203	LMX	
Dunn, Paul	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	A203	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+		+				LMX	
Esteves Kondo,	29	+	+	+	+	+	+	+	+		+	+	+	+	+	+		+	+			+					LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					LMX	
Hahn, Amy B. P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+				LMX	
Hamdi, Nuha	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Hogan,Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Holdsworth, Rho		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+			B56	LMX	
Klein, Tirza	26	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+			+			LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+								LMX	
Loewenthal , Ro	100	+	+	+	+	+	+	+	+	+	+	+	+				+	+			+	+				B60,B61,B48,B78 >	LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+				B56	LMX	
Mani, Rama	96	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+		+			+			CW4,CW6,B60,B61 >	LMX	
Martinho, Paiva		+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+				+			B56	LMX	
Meyer, Pieter W	26	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+								LMX	
Pancoska, Carol	31	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					LMX	
Permpikul, Vejba		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					LMX	
Ramon, Daniel F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	+	+	LMX	
Reed, Elaine F.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Rosen-Bronson,	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					LMX	
Suciu-Foca, Nicu		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	+	+	LMX	
Terasaki, Paul I.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					LMX	
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	A203	LMX

Table 40. Individual laboratory results for Serum #1166 Luminex

		**** Serum 1166 ****																																						
Investigator	% POS	A25	A26	B35	A30	A3	A34	A36	B18	B45	B60	B72	B7	A43	B50	B55	B75	B42	B56	B62	B61	A1	B41	B76	B81	B8	B39	A74	A11	A31	B71	A29	A33	A68	B48	B67	Other	Method		
Alvarez/Carretto	40	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27,B54,B8101,B7801 >	LMX	
Brouard, Tabary	49	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40,A80,B64,B8101 >	LMX	
Cecka, J. Michal	60	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B27,A80	LMX	
Chen, Dong-Fen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B54,A32,A69,A80 >	LMX	
Dunn, Paul	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A66,B78,B27 >	LMX	
Eckels/CPMC, Esteves Kondo,	45	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B78,B82,B54 >	LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A66,B78,B27 >	LMX	
Hahn, Amy B. P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B27,A32,A80	LMX	
Hamdi, Nuha	73	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B27,A32,A80	LMX	
Hogan,Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B78,B27,B82 >	LMX	
Holdsworth, Rho		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A66,B78,B27 >	LMX	
Klein, Tirza	34	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40,A66,B27,B82 >	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B78,B82,B54 >	LMX
Loewenthal , Ro	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B78,B44,B27 >	LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A66,B78,B44 >	LMX
Mani, Rama	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A24,B78 >	LMX	
Martinho, Paiva		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B78,B49,B47 >	LMX	
Meyer, Pieter W	41	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40,B15,A66,B78 >	LMX	
Pancoska, Carol	68	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B78,B27,B54 >	LMX	
Permpikul, Vejba		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B27,A32,A80	LMX	
Ramon, Daniel F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A32,A80,B64,B2708 >	LMX
Reed, Elaine F.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B78,B82,B54 >	LMX
Rosen-Bronson,	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A66,B78,B27 >	LMX
Suciu-Foca, Nicu		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B27,B82,B54 >	LMX
Terasaki, Paul I.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B78,B27,A32 >	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B27,B8101,B2708 >	LMX

Table 41. Individual laboratory results for Serum #1167 Luminex

		**** Serum 1167 ****																																						
Investigator	% POS	A1	A30	B57	A23	A24	B27	A36	B58	B63	B42	B54	B55	B56	A3	A43	B7	B76	B82	B44	B45	A11	A80	A25	B67	B81	A26	A29	B75	CW18	CW17	A2403	A66	A6601	CW6	Other	Method			
Alvarez/Carretto	39	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		+	+	+		+	+	+	+							B61,B48,B49,B47 >	LMX		
Brouard, Tabary	60	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+																				B8101,B2708,A1101,A1102 >	LMX	
Cecka, J. Micha	53	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				LMX
Chen, Dong-Feng PhC		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,A34,B8101,B2708 >	LMX	
Dunn, Paul	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A34,B2708,A1101,A1102	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B2708	LMX	
Esteves Kondo,	34	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Hamdi, Nuha	80	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Hogan,Patrick		+	+	+	+	+	+	+	+	+					+	+		+	+				+																LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,A34	LMX	
Klein, Tirza	26	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B15	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+									+	+																			LMX	
Loewenthal , Ro	94	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+	+	+	+	+			+	+								+		B48,B78,B62,B49 >	LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,B13,A34	LMX	
Mani, Rama	88	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B48,B78,B62,B50 >	LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Meyer, Pieter W	25	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B15	LMX	
Pancoska, Carol	52	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Permpikul, Vejbaesya		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Ramon, Daniel PhD		+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B2708,A1101,A1102,B8201	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,A34,CW5,CW15	LMX
Rosen-Bronson,	92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Suciu-Foca, Nicole Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A1101,A1102	LMX
Terasaki, Paul I. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,B2708,A1101,A1102 >	LMX

Table 42. Individual laboratory results for Serum #1168 Luminex

		**** Serum 1168 ****																																								
Investigator	% POS	A25	A31	A32	A33	A34	A36	A69	A74	B41	B42	B7	B8	A1	A26	A29	A3	A30	A68	B60	A43	B73	B81	A80	B48	A11	B75	CW18	CW7	A66	B38	B67	B61	B39	CW6	B77	Other	Method				
Alvarez/Carretto	36	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,A1101,A1102,A6601>	LMX		
Brouard, Tabary	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW10,CW9,A1101,A1102 >	LMX		
Cecka, J. Michal	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX		
Chen, Dong-Fen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B50,B47,B44,B8101 >	LMX		
Dunn, Paul	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B13,B47 >	LMX		
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A6601,A6602	LMX		
Esteves Kondo,	40	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX			
Hahn, Amy B. P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B47,B44	LMX		
Hamdi, Nuha	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW10	LMX		
Hogan,Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX		
Holdsworth, Rho		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B13,B47 >	LMX		
Klein, Tirza	39	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40	LMX		
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX		
Loewenthal , Ro	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B62,B49,B13 >	LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B47,B44,A28,B18 >	LMX	
Mani, Rama	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,B78,B62 >	LMX	
Martinho, Paiva		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B62,B49,B50 >	LMX	
Meyer, Pieter W	34	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40	LMX	
Pancoska, Carol	76	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW10	LMX	
Permpikul, Vejba		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX	
Ramon, Daniel F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A1101,A1102,A6601,A6602>	LMX
Reed, Elaine F.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B13,B47 >	LMX
Rosen-Bronson,	92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B13,B47 >	LMX
Suciu-Foca, Nico		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B47,B44 >	LMX
Terasaki, Paul I.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW10	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,A1101,A1102,A6601>	LMX

Table 43. Individual laboratory results for Serum #1165-#1168 by Flow Cytometry and Elisa

**** Serum 1165 ****												**** Serum 1166 ****													
Investigator	% POS											Other	% POS											Other	Method
Eckels/CPMC	95												99												FC

**** Serum 1167 ****												**** Serum 1168 ****													
Investigator	% POS											Other	% POS											Other	Method
Eckels/CPMC	97												99												FC

FC = Flow Cytometry

**** Serum 1165 ****																	**** Serum 1166 ****																											
Investigator	% POS	A1	A11	A2	A25	A26	A29	A30	A31	A33	A34	A36	A66	A68	A69	A74	A80	Other	% POS	A11	A25	A26	A29	A3	A36	A66	A80	B35	B39	B41	B42	B45	B48	B50	B54	B55	B60	B61	B72	B75	Other	Method		
Esteves Kond	28	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		61	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B81,B27>	Elisa
Hahn, Amy B.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A3		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B81,B27>	Elisa

**** Serum 1167 ****																	**** Serum 1168 ****																																			
Investigator	% POS	A1	A11	A23	A24	A25	A26	A29	A3	A30	A36	A80	B27	B42	B44	B45	B54	Other	% POS	A1	A11	A25	A26	A29	A3	A30	A31	A32	A33	A34	A36	A66	A68	A69	A74	A80	B37	B41	B42	B44	Other	Method										
Esteves Kond	48	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B55,B56>	46	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B48,60>	Elisa	
Hahn, Amy B.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B55,B56>		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B48,60>	Elisa

Table 44. Individual laboratory results for Serum #1165-#1168 by NIH-Standard, Other, and Flow Cytometry - class II

	**** Serum 1165 ****						**** Serum 1166 ****			**** Serum 1167 ****				**** Serum 1168 ****								
Investigator	% POS	DR4				Other	% POS	DR4	Other	% POS	DR7	DR9	Other	% POS	DQ7	DQ8	DQ9	DR14		Other	Method	
Claas, F.H.J.	42	+					33	+		21	+			46				+				STD
Reed, Elaine F.	85						56			51	+	+		73	+	+	+					STD

	**** Serum 1165 ****							**** Serum 1166 ****			**** Serum 1167 ****				**** Serum 1168 ****											
Investigator	% POS	DQ7	DQ8	DQ9	DR1	DR10	DR4	Other	% POS	DR18	DR4	Other	% POS	DR53	DR7	DR9	Other	% POS	DQ7	DQ8	DQ9	DR11	DR4	DR8	Other	Method
Reed, Elaine F.	96	+	+	+	+	+	+		98	+	+		86	+	+	+		98	+	+	+	+	+	+		Other

	**** Serum 1165 ****						**** Serum 1166 ****			**** Serum 1167 ****				**** Serum 1168 ****											
Investigator	% POS					Other	% POS		Other	% POS		Other	% POS				Other	% POS						Other	Method
Eckels/CPMC,	96						49			88			95					95							FC

STD = NIH-Standard
 FC - Flow Cytometry

Table 45. Individual laboratory results for Serum #1165-#1166 by Luminex - class II

Investigator	**** Serum 1165 ****																Other	**** Serum 1166 ****							Method
	% POS	DR1	DR10	DR4	DQ4	DR15	DR14	DQ7	DQ8	DQ9	DR13	DR51	DQ2	DR16	DR17	DR8		% POS	DR4	DR53	DR9	DR18	DR8	Other	
Brouard, Tab	71	+	+	+	+	+	+	+	+	+	+	+	+					26	+	+					LMX
Cecka, J. Mic	71	+	+	+	+	+	+	+	+	+	+	+						26	+						LMX
Chen, Dong-F		+	+	+	+	+	+	+	+	+	+	+				+			+	+					LMX
Dunn, Paul	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	56	+	+	+		+	DR10	LMX
Eckels/CPMC		+	+	+	+	+	+	+	+	+	+								+	+					LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+		LMX
Hahn, Amy B.		+	+	+	+	+	+	+	+	+	+								+	+					LMX
Hamdi, Nuha	71	+	+	+	+	+	+	+	+	+		+	+					40	+	+	+		+	DR10	LMX
Hogan, Patrick		+	+	+	+	+	+	+	+	+		+							+	+	+	+		DR7	LMX
Holdsworth, R		+	+	+	+	+	+	+	+	+	+	+		+	+	+			+	+	+	+		DR10	LMX
Klein, Tirza	38	+	+	+	+	+	+											23	+					DR3,DR12	LMX
Mani, Rama	93	+	+	+	+	+	+	+	+	+	+	+		+		+		50	+	+	+	+	+	DR7,DR17	LMX
Meyer, Pieter	43	+	+	+	+	+	+				+							12	+		+			DR3,DR7	LMX
Pancoska, Ca	46	+	+	+	+	+	+	+	+	+	+	+	+					14	+	+					LMX
Permpikul, Ve		+	+	+				+	+	+		+		+					+	+		+		DR10,DQ4,DQ	LMX
Ramon, Danie		+	+	+	+	+	+	+	+	+	+	+	+						+	+					LMX
Reed, Elaine I		+	+	+	+	+	+	+	+	+	+					+			+	+	+		+		LMX
Rosen-Bronsc	89	+	+	+	+	+	+	+	+	+	+	+						53	+	+		+			LMX
Turner, E.V. F		+	+	+	+	+	+	+	+	+		+	+						+	+					LMX

Table 46. Individual laboratory results for Serum #1167-#1168 by Luminex - class II

	**** Serum 1167 ****																**** Serum 1168 ****											
Investigator	% POS	DR12	DR7	DR9	DR53	DP13	DP14	DP17	DPW1	DPW5	DPW3	DP10	DP11	DP15	DP9	DPW6	DR10	DP18	DR52	DPW4	Other	Method						
Brouard, Tab	77	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX					
Cecka, J. Mic	77	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX					
Chen, Dong-F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DR14		LMX					
Dunn, Paul	68	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ8,DQ9		LMX					
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX					
Fort, Marylise																							LMX					
Hahn, Amy B.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX					
Hamdi, Nuha	77	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX					
Hogan,Patrick		+	+	+	+	+	+	+	+	+	+							+	+	+			LMX					
Holdsworth, R		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX					
Klein, Tirza	87	+	+	+													+				DR3,DR4,DR13>		LMX					
Mani, Rama	73	+	+	+	+														+		DR4,DR14,DR18		LMX					
Meyer, Pieter	38	+	+	+													+				DR4		LMX					
Pancoska, Ca	45	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX					
Permpikul, Ve		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+			LMX					
Ramon, Danie		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ9		LMX					
Reed, Elaine I		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ7		LMX					
Rosen-Bronsc	90	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX					
Turner, E.V. F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX					
																							LMX					

NEXT MAILING DATE: March 4, 2015
Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed